US 20090156563A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156563 A1 Baschong et al. (43) Pub. Date: Jun. 18, 2009

(54) GLUCAN COMPOSITIONS Publication Classification (76) Inventors: Werner Baschong, Basel (CH): (51) Int. Cl. Sebastien Mongiat, Sierentz (FR): A613/60 (2006.01) Dietmar Ochs, Schopfheim (DE) A6IP 700 (2006.01) Correspondence Address: (52) U.S. Cl...... S14/159 JoAnn Villamizar Ciba Corporation/Patent Department (57) ABSTRACT 540 White Plains Road, P.O. Box 2005 A cosmetic or pharmaceutical composition is provided com Tarrytown, NY 10591 (US) prising: a) 0.001 to less than 0.2% by weight, based on the weight of the total composition, of a Scleroglucan having a (21) Appl. No.: 12/085,271 mean molecular weight of 1x10° to 12x10; b) a cosmetically or pharmaceutically acceptable carrier, and, optionally, c) (22) PCT Fled: Nov. 20, 2006 lactic acid, a lactate and/or pentanediol. The composition shows advantageous effects. Such as moisturization of skin or (86) PCT NO.: PCT/EP2006/068645 mucosa, and has an antiaging and revitalizing effect on the skin. When combined with a certain bactericide as explained S371 (c)(1), in claim 1, compositions containing native polysaccharides of (2), (4) Date: May 20, 2008 the glucan class in general, especially of the Scleroglucan as (30) Foreign Application Priority Data of componenta), are well suitable to reduce the number of bacteria in mucosal or oral environments and minimise adhe Nov.30, 2005 (EP) ...... O5111504.6 Sion, while retaining a pleasant feeling on the mucosa or Jul. 7, 2006 (EP) ...... O61167664 gingiva. Plaque thus can be efficiently prevented or removed. US 2009/0156563 A1 Jun. 18, 2009

GLUCAN COMPOSITIONS 0010. The lactate often is sodium lactate, preferred as component c) thus are sodium lactate and/or 1.2-pentanediol. Component c) is preferably used in an amount of 0.005 to 3, 0001. The present invention relates to compositions useful especially 0.02 to 1.0% by weight, relative to the weight of the in the field of cosmetics and pharmaceuticals, especially skin total product composition. cosmetics and dermatological compositions, containing a 0011 Specifically, the weight ratio used of component (c) low concentration of a specific polysaccharide of the Sclero relative to component (a) (c.a) often is from the range 1:1 to glucan class, and optional further components like lactate or 30:1, for example 2:1 to 20:1, especially about 2-12 or 5-10 pentanediol. The present invention further relates to antibac parts by weight of lactic acid or a lactate Such as sodium terial compositions for contact with the mucosa Such as an lactate and/or 5-20, especially 8 to 18 parts by weight of oral care or feminine hygiene composition, which contain 1.2-pentanediol, on one part by dry weight of the Scleroglu synergistic mixture of a glucan, especially the above Sclero can in component (a). glucan, and a specific bactericide. 0012 Polysaccharides of the scleroglucan class useful in 0002 EP-A-655904 recommends 1,2-pentanediol as a the present invention are known e.g. from U.S. Pat. No. 5,814, skin moisturizer. 341, U.S. Pat. No. 6,162,447 and U.S. Pat. No. 6,162,449. 0003 U.S. Pat. No. 5,814,341 describes the use of B-1,3- The scleroglucan to be used in the present invention is to be Scleroglucans for the preparation of stable and transparent understood as a product which may be isolated from the fungi gels. In U.S. Pat. No. 6,162,447 and U.S. Pat. No. 6,162,449, Sclerotium, Lentillium or Schizophyllium (thus also called the preparation of Such polysaccharides by cultivation of Scleroglucan, lentinan, Schizophyllan) and may be been microorganisms is explained, and personal care formulations, obtained by cultivation of microorganisms in a manner as including microemulsions, containing these Scleroglucans described in the US patents cited above, preferably microor are disclosed, interalia effecting skin lubrication, moisturiza ganisms in the form of the plant-pathogenic fungi imperfecti tion, film formation and improvement of skin sensory prop Sclerotium rolfsii. erties, and/or acting as dispersion aid or (co)emulsifier, thick 0013 Scleroglucanes of the present class are also recalled ening agent, retention aid for other active ingredients. High as B-1.3(1,6)-glucanes or 3-1,3-scleroglucanes. The polysac charide chains usually form a three-dimensional structure of amounts of Scleroglucan are generally used according to triple helices; polymer chains essentially consist of glucose these documents, especially in skin applications. units whose hydroxy groups in 1- and 3-position are B-linked 0004 JP-A-2001031541 and WO99/32073 teach the use to form the polymer main chain, and wherein each 3"glucose of a native polysaccharide such as a B-D-glucan or a modified unit contains in position 6 a further glucose moiety linked by polysaccharide Such as a phosphochitosan in an oral compo its 1-OH funktion (B-1,3-bonded glucopyranose as the main sition, e.g. for the prevention and control oftooth tartar, dental chain and B-1,6-bonded glucopyranose as side chains) and plaque, or periodontitis. has the structural formula: 0005. These dental affections, like caries or a group of mucosal diseases, are largely caused by the attack of micro organisms such as bacteriae. Their harmful action is often enhanced by their ability to adhere to their substrate, forming a biofilm especially on hard tissue or hard tissue/soft tissue interfaces. Further they may produce harmful enzymes or O other agents such as alkaline phosphatase, and by rapid pro liferation. OH 0006. A combination of a certain glucosamin with chlo HO rohexidine has been reported to strongly reduce infestation of O O oral environments with bacteriae (see Decker et al., J. Peri O O dont Res. 40, 373 (2005)). OH OH 0007. It has now been found, that the amount of scleroglu can used in formulation applied to or in contact with the skin Surprisingly may be greatly reduced while advantageous in which n is a number which provides the B-1,3-scleroglucan effects are retained or even improved, especially with con component with a mean molecular weight (MW) of 1 x06 to comitant use of a further component as explained below. It 12x10, preferably 2x10 to 10x10°. All molecular weights has further been found that this use plays an antiaging and (MW) noted are determined from the readily measured revitalizing effect on the skin. Staudinger Index musing the following Mark-Houwink equa 0008 Subject of the Invention Thus is a Composition tion: Comprising MW =m/4x45x10-71/149. a) 0.001 to 0.2%, or less than 0.2%, relative to the weight of 0014 Preferably, a 0.3 g/l aqueous solution of the f-1,3- the total composition, of a Scleroglucan of mean molecular Scleroglucan has a glucose content below 0.1 g/l and a vis weight 110° to 12:10: cosity of 50 to 190 mPa's, measured at a shear rate of 0.3 s' b) a cosmetically or pharmaceutically acceptable carrier, and at 20° C. c) a further component selected from lactic acid, lactate and 00.15 Preferred is the B-1,3-scleroglucan produced using 1.2-pentanediol. the plant-pathogenic fungi imperfecti Sclerotium rolfsii 0009. In the cosmetic or pharmaceutic end product, com ATCC 15205 (U.S. Pat. No. 6,162,447 and U.S. Pat. No. ponent a) is mainly used in a concentration from 0.001 to 6,162,449). 0.1%, especially 0.005 to less than 0.05% by weight, relative 0016 Though of relatively high molecular weight, the to the weight of the total product composition. present glucane component, especially the Scleroglucanes US 2009/0156563 A1 Jun. 18, 2009

described above, are soluble in aqueous solutions. In conse salts; hexetidine; 5-bromo-5-nitro-1,3-dioxane: bronopol; quence, essentially no increase in turbidity is caused by addi 2,4-dichlorobenzyl alcohol; triclocarban; Triclosan; tion of the present glucan component. Compositions of the 4-chloro-3,5-xylenol; imidazolidinyl urea; poly(1-hexameth invention are mainly useful in the field of cosmetics and ylenebiguanide hydrochloride); 2-phenoxyethanol; hexam pharmaceuticals especially for the skin treatment, e.g. as cos ethylenetetramine; methenamine 3-chloroallylochloride: metical or dermatological skin composition. 1-(4-chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan 0017. It has been found that the combination of the sclero 2-one; 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine glucan with a lactate such as Sodium lactate, and/or with 2,4-dione; benzyl alcohol; 1-hydroxy-4-methyl-6(2,4,4-tri 1.2-pentanediol in the formulation acts in an especially methylpentyl)-2-pyridon or its monoethanolamine salt; advantageous manner as a moisturizer or lubricant on the skin methyldibromoglutaronitrile; bromochlorophen; 4-isopro or mucosa. Formulations containing the combination of the pyl-m-cresol; mixture of 5-Chloro-2-methyl-isothiazol-3 Scleroglucan with lactate show further advantageous effects (2H)-one and 2-methylisothiazol-3(2H)-one with magne including improved stability of the formulation under high- or sium chloride and magnesium nitrate; clorophene; low temperature storage conditions (e.g. at 0-10° C.) and 2-chloroacetamide; chlorhexidine and its digluconate, diac improved resistance against microbial attack. etate and/or dihydrochloride: 1-phenoxypropan-2-ol; alkyl 0018. The composition of the invention preferably is in the (C-C) trimethyl ammonium bromide and/or chloride; form of a gel or viscous liquid (e.g. of Viscosity range 4,4-dimethyl-1,3-oxizalidine: N-(hydroxymethyl)-N-(dihy 2-100000 cp, especially 10-20000 cp at 20° C. droxymethyl-1,3-dioxo-2,5-imidazolidinyl-4)-N'-(hy (cp=centipoise)). droxymethyl)urea; hexamidine and its salts; glutaraldehyde; 0019. It has further been found that the present scleroglu chlorphenesin; sodium hydroxymethylglycinate; benzetho can formulation plays an antiaging effect or contributes to nium chloride; benzalkonium chloride, bromide and/or sac Such an effect, e.g. by charinate; benzylhemiformal, listerine, alexidine. Chlorhexi 0020 improving the appearance of the skin and helping dine may be in free form or any of its application forms such in the wound healing, as the gluconate or acetate or hydrochloride. 0021 reduction of wrinkle depth and height; and plays 0029 Salts and other derivatives such as esters in the fol a revitalizing effect on the skin's active defense system lowing, more detailed list ofbactericides useful as component (skin immune system) by b), are to be understood as cosmetically or pharmacologi 0022 protecting against the damaging effects of UV cally, depending on the intended end-use, acceptable salts and radiation and photooxidation, especially on the Langer derivatives (percentages are preferred amounts, given by hans cells, weight relative to the total composition; most preferred is a 0023 activating the Langerhans cells, and dosage within the range of about 50% of the upper limit and 0024 promoting the growth of keratinocytes. the upper limit of range given): 0025. As has now been found, extremely low amounts of Benzoic acid, its salts and esters 0.01-0.05, especially 0.05 the Scleroglucan may be used, while its advantageous effects 0.5% b.w. of acid; are retained or even improved; especially worth emphasizing Propionic acid and its salts 0.01-2% b.w. of acid; are the high degree of moisturization, and skin effects such as Salicylic acid and its salts 0.01-0.5% b.w. of acid; reduced Stickiness, reduced roughness, improved softness, Sorbic acid (hexa-2,4-dienoic acid) and its salts 0.01-0.6% general skin health. b.w. of acid; 0026. A further aspect of the invention thus is a composi Formaldehyde or paraformaldehyde 0.01-0.2% (not for oral tion, especially a cosmetical or dermatological skin compo compositions) or 0.01-0.1% (oral compositions); sition, comprising 0.001 to less than 0.05% by weight, espe Biphenyl-2-ol (o-phenylphenol) and its salts 0.01-0.2%; cially 0.005 to less than 0.05% by weight, relative to the Inorganic sulphites and hydrogen sulphites 0.01-0.2% b.w. of weight of the total composition, of a B-1,3-scleroglucan of free SO; mean molecular weight 110° to 12:10, and a cosmetically or Sodium iodate 0.01-0.1%: pharmaceutically acceptable carrier. Chlorobutanol (INN) 0.01-0.5%; 0027. It has been a further finding of the invention, that 0030 4-Hydroxybenzoic acid and its salts and esters 0.01 native polysaccharides of the glucan class are especially well 4% b.w. of acid, especially 0.01-0.8% b.w. of acid, e.g. when suitable to reduce the number of bacteria in mucosal or oral using a mixture of esters; environments and minimise adhesion, when combined with a 3-Acetyl-6-methylpyran-2,4(3H)-dione (Dehydracetic acid) Suitable bactericide, while retaining a pleasant feeling on the and its salts 0.01-0.6% b.w. of acid; mucosa or gingiva. Plaque can be efficiently prevented or Formic acid and its sodium salt 0.01-0.5% b.w. of acid; removed. 3,3'-Dibromo-4,4'-hexamethylenedioxydibenzamidine (Di 0028 Subject of the invention thus is an antibacterial com position for contact with the mucosa and other tissues of the bromohexamidine) and its salts (including isethionate) 0.01 oral cavity, which is characterized by containing 0.1%; a) a glucan and Undec-10-enoic acid and salts 0.01-0.2% b.w. of acid; b) a bactericide selected from benzoic acid, its salts and Hexetidine (INN) 0.01-0.1%; esters; propionic acid and its salts; salicylic acid and its salts; Sorbic acid and its salts; formaldehyde; paraformaldehyde; 0031 5-Bromo-5-nitro-1,3-dioxane 0.01-0.1%: o-phenylphenol and its salts; inorganic Sulphites and hydro Bronopol (INN) 0.01-0.1%: gen Sulphites; sodium iodate; chlorobutanol, 4-hydroxyben 0032 2,4-Dichlorobenzyl alcohol 0.01-0.15%: Zoic acid and its salts and esters; 3-acetyl-6-methylpyran-2, 4(3H)-dione: formic acid; Sodium formiate; Triclocarban (INN) 0.01-0.2%; dibromohexamidine and its salts; undec-10-enoic acid and Triclosan (INN) 0.01-0.3%: US 2009/0156563 A1 Jun. 18, 2009

0033 4-Chloro-3,5-xylenol 0.01-0.5%; agents; essential oils including thymol, geraniol, carvacrol, 3,3'-Bis (1-hydroxymethyl-2,5-dioxoimidazolidin-4-yl)-1, citral, hinokitiol, eucalyptol, eugenol, menthol, catechol; and 1'-methylenediurea (Imidazolidinyl urea) 0.01-0.6%; mixtures thereof. Poly (1-hexamethylenebiguanide hydrochloride 0.01-0.3%: 0040 Also important are bactericides selected from 2-phenylphenol, 2.4.4'-trichloro-2'-hydroxy-diphenylether 2-Phenoxyethanol 0.01-10%: (Triclosan), 4,4'-dichloro-2-hydroxydiphenylether, 2,2'-me 0034. Hexamethylenetetramine (methenamine) (INN) thylene-bis-(4-chloro-phenol), 4-(2-t-butyl-5-methylphe 0.01-0.15%: noxy)-phenol, 3-(4-chlorophenyl)-1-(3,4-dichloro-phenyl)- Methenamine 3-chloroallylochloride (INNM) 0.01-0.2%; urea, chlorhexidine in free form or any of its application 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan forms such as the gluconate or acetate or hydrochloride, hex 2-one 0.01-0.5%; etidine, benzalkonium chloride. Most important are Tri 1,3-Bis (hydroxymethyl)-5,5-dimethylimidazolidine-2,4-di closan, chlorohexidin, hexetidine, listerine. one 0.01-0.6%; Benzyl alcohol 0.01-1.0%; 0041 Essential oils are often added as additional compo 1-Hydroxy-4-methyl-6(2,4,4-trimethylpentyl) 2-pyridon or nents besides one of the other bactericides mentioned, espe its monoethanolamine salt 0.01-1%; cially in oral care compositions. 1,2-Dibromo-2,4-dicyanobutane (methyldibromoglutaroni 0042. Of special importance is an oral care composition trile) 0.01-0.1%; containing as component b) an anti-microbial agent selected 6,6-Dibromo-4,4-dichloro-2,2'-methylenediphenol (Bromo from 5-chlor-2-(2,4-dichlorophenoxy)-phenol (Triclosan), chlorophen) 0.01-0.1%; Silver Dihydrogen Citrate, Phthalic acid and its salts, alexi dine, hexetidine, Sanguinarine, benzalkonium chloride, Sali 4-Isopropyl-m-cresol 0.01-0.1%; cylamilide, domiphen bromide, cetylpyridinium chloride, 0035 Mixture of 5-Chloro-2-methyl-isothiazol-3(2H)- tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyri one and 2-methylisothiazol-3(2H)-one (especially in the ratio dinium chloride, octenifine, delmopinol, octapinol and other 3:1) with magnesium chloride and magnesium nitrate piperidine derivatives, nicin preparations, Zinc? stannous ion 0.0005-0.0015%; agents, essential oils including thymol, geraniol, carvacrol, 2-Benzyl-4-chlorophenol (clorophene) 0.01-0.2%; citral, hinokitiol, eucalyptol, catechol and mixtures thereof. 0043. The composition contains the glucan usually in an 2-Chloroacetamide 0.01-0.3%: amount of 0.001 to 0.2%, such as 0.001 to 0.1, especially 0036 Chlorhexidine (INN) and its digluconate, diacetate 0.005 to less than 0.05% by weight, relative to the weight of and/or dihydrochloride 0.01-0.3% b.w. of chlorhexidine: the total composition. The preferred glucan is a Scleroglucan of mean molecular weight 1:10 to 12:10. The weight ratio 1-Phenoxypropan-2-ol 0.01-1.0%; bactericide:glucan is usually from the range 1:10-10:1. 0037 Alkyl (C12-C22) trimethyl ammonium, bromide 0044 Native polysaccharides of the glucan class useful in and/or chloride 0.01-0.1%: the present invention usually are B-linked glucanes. Such as 4,4-dimethyl-1,3-oxizalidine 0.01-0.1% (in finished product 1,3-beta-glucanes e.g. of plant, bacterial or especially fungal of pH 6 or higher); origin. They often contain side chains in 6-position (1,3-1,6- N-(Hydroxymethyl)-N-(dihydroxymethyl-1,3-dioxo-2,5- B-glucan type), preferred glucanes of this type are Scleroglu imidazolidinyl-4)-N'-(hydroxymethyl)urea 0.01-0.5%; cans known e.g. from U.S. Pat. No. 5,814,341, U.S. Pat. No. 1,6-Dii (4-amidinophenoxy)-n-hexane (Hexamidine) and its 6,162,447 and U.S. Pat. No. 6,162,449. The scleroglucan to be used in the present invention is to be understood as a salts (including isethionate and p-hydroxybenzoate) 0.01-0. product which may be isolated from the fungi Sclerotium, 1%; Lentillium or Schizophyllium (thus also called Scleroglucan, Glutaraldehyde (Pentane-1,5-dial) 0.01-0.1%; lentinan, Schizophyllan) and may be been obtained by culti 3-(p-chlorophenoxy)-propane-1,2 diol (chlorphenesin) 0.01 Vation of microorganisms in a manner as described in the US 0.3%: patents cited above, preferably microorganisms in the form of Sodium hydroxymethylamino acetate (Sodium Hydroxym the plant-pathogenic fungi imperfecti Sclerotium rolfsii. In ethylglycinate) 0.01-0.5% Benzethonium chloride general, preferred features of the native polysaccharides of 0.01-0.1%; the glucan class useful in combination with the bactericide as Benzalkonium chloride, bromide and/or saccharinate 0.01-0. described are identical with the Scleroglucan classes 1% (b.w. calculated as benzalkonium chloride; not for eye described further above. care formulations); 0045 Compositions of the invention, especially those containing the lactate and/or 1.2-pentanediol component c), Benzylhemiformal 0.01-0.15%; or glucan plus bactericide, are usually not prepared by adding 0038 Listerine (5-methyl-2-(1-methylethyl)-phenol the pure components a) and c) in the required amounts to the mixed with 5-methyl-2-(1-methylethyl)cyclohexanol and desired end formulation; instead, a concentrated formulation 1,3,3-trimethyl-2-oxabicyclo(2.2.2)octane) 0.01-0.5%. usually is prepared as a first step, containing componenta) in 0039. Preferred bactericides of component b) are selected a concentration that provides good handling especially with from 5-chlor-2-(2,4-dichlorophenoxy)-phenol (Triclosan), regard to the viscosity of the formulation, good storage sta alexidine, hexetidine, benzalkonium chloride, salicylamide, bility, and easy dosability of the concentrate. The invention domiphen bromide, tetradecylpyridinium chloride, N-tet therefore also pertains to a concentrate for the preparation of radecyl-4-ethylpyridinium chloride, octenifine, delmopinol, a cosmetic orpharmaceutical formulation, which concentrate octapinol and other piperidine derivatives, Zinc?stannous ion is characterized by containing US 2009/0156563 A1 Jun. 18, 2009 a) about 0.3 to 3% by weight, e.g. about 1.0% by weight, creams, face powder (loose or pressed), rouge or cream make relative to the total weight of the concentrate, of the polysac up, eye-care preparations, e.g. eyeshadow preparations, mas charide (Scleroglucan as described above for componenta), cara, eyeliner, eye creams or eye-fix creams; lip-care prepa b) a cosmetically or pharmaceutically acceptable carrier, rations, e.g. lipsticks, lip gloss, lip contour pencils, nail-care which usually is an aqueous carrier Such as water, physiologi preparations, such as nail varnish, nail varnish removers, nail cal or near physiological solution of Sodium chloride, or a hardeners or cuticle removers; foot-care preparations, e.g. suitable buffer solution, and footbaths, foot powders, foot creams or footbalsams, special c) lactate and/or 1.2-pentanediol in a weight ratio relative to deodorants and antiperspirants or callus-removing prepara component (a) from the range 2:1 to 20:1; tions; light-protective preparations, such as Sun milks, and further to a concentrate, which may be characterized by lotions, creams or oils, Sunblocks or tropicals, pre-tanning containing preparations or after-Sun preparations; skin-tanning prepara a) about 0.3 to 3% by weight, e.g. about 1.0% by weight, tions, e.g. Self-tanning creams; depigmenting preparations, relative to the total weight of the concentrate, of the polysac e.g. preparations for bleaching the skin or skin-lightening charide (e.g. Scleroglucan as described above), preparations; insect-repellents, e.g. insect-repellent oils, b) a bactericide as described above, and optionally lotions, sprays or sticks; deodorants, such as deodorant c) lactate and/or 1.2-pentanediol in the amount desired (see sprays, pump-action sprays, deodorant gels, Sticks or roll above), and ons; antiperspirants, e.g. antiperspirant sticks, creams or roll d) a cosmetically or pharmaceutically acceptable carrier, ons; preparations for cleansing and caring for blemished skin, which usually is an aqueous carrier Such as water, physiologi e.g. synthetic detergents (solid or liquid), peeling or scrub cal or near physiological solution of Sodium chloride, or a preparations or peeling masks, shaving preparations, e.g. suitable buffer solution. shaving Soap, foaming shaving creams, non-foaming shaving 0046. The concentrate may contain further components creams, foams and gels, preshave preparations for dry shav required for the preparation of the desired end formulation; ing, aftershaves or aftershave lotions; fragrance preparations, often, however, it will consistessentially of these components e.g. fragrances (eau de Cologne, eau de toilette, eau de par as described above. fum, parfum de toilette, perfume), perfume oils or perfume 0047 The cosmetic composition may constitute, e.g., a creams such as an emulsion or cream in which the Scleroglu shampoo, rinse, gel and/or hair conditioner, hair-removal can a) optionally in combination with component c) may preparations (e.g. hair-removing powders, liquid hair-remov perform one or more of the following functions: ing preparations, cream- or paste-form hair-removing prepa i) effect a lubricating function, thereby facilitating the spread rations, hair-removing preparations in gel form or aerosol ing of the composition on the skin; foams), cosmetic hair treatment preparations such as, e.g., ii) act as a film-forming agent, thereby providing a protective hair-washing preparations in the form of shampoos and con film on the skin, which film, while almost undetectable by ditioners, hair-care preparations, e.g. pretreatment prepara touching, provides the skin with a silky feel; tions, hair tonics, styling creams, styling gels, pomades, hair iii) effect a smoothing of the skin by reducing the scaling of rinses, treatment packs, intensive hair treatments, hair-struc the outermost layer of stratum corneum; turing preparations, e.g. hair-waving preparations for perma iv) effect an anti-inflammatory effect on the skin; nent waves (hot wave, mild wave, cold wave), hair-straight ening preparations, liquid hair-setting preparations, hair V) effect an improvement in the dispersion of other compo foams, hairsprays, bleaching preparations, e.g. hydrogen per nents of the skin care composition; and oxide solutions, lightening shampoos, bleaching creams, vi) act as an emulsifier or co-emulsifier for the skin care bleaching powders, bleaching pastes or oils, temporary, semi composition. permanent or permanent hair colourants, preparations con 0049. The present antibacterial compositions are suitable taining self-oxidising dyes, or natural hair colourants, such as for contact with the mucosa or tissues of the oral cavity; they henna or chamomile, wherein the Scleroglucan componenta) may be formulated inter alia as an oral care or feminine optionally in combination with component c) may perform hygiene composition Such as a feminine hygiene washing one or more of the following functions: lotion or spray, or a composition for the treatment of a medi i) effect an improvement in the combability of hair treated cal, especially oral, implant (prior or after nidation), or a with the shampoo/conditioner; denture or brace. The present composition may also be used ii) effect an improvement in the dispersion of other compo as an eye drop formulation, an eye make-up (e.g. eyeliner, eye nents in the shampoof conditioner; iii) act as a smoothing cream or eye-fix cream) or an eye make-up remover. agent for hair treated with the shampoof conditioner, and 0050 Preferred are oral care compositions including tooth iv) effect an improvement in the level of fixing of such addi pastes or gels, mouth washes, gargles, inhalants, denture or tives as dyes or UV absorbers in the shampoo/conditioner. implant or brace or cleaner thereof, adhesive paste. 0048. The cosmetic or pharmaceutic composition accord 0051. In oral compositions, a combination with a further ing to the present invention may also constitute a skin care agent Suitable to inhibit alkaline phosphatase is preferred. composition, e.g., anti-wrinkle-product; lip-care formula Such agents may, for example, be selected from polyanionic tion; moisturizing cream; wound-care-formulation; skin and polyanionically-derivatised “natural polysaccharides, washing and cleansing preparations in the form of tablet-form e.g. phosphochitosanes or especially phosphonochitosanes, or liquid soaps, Soapless detergents or washing pastes; bath as described in WO 99732073. preparations, e.g. liquid (foam baths, milks, shower prepara 0.052 The glucan often contains a further component (c) tions) or Solid bath preparations, e.g. bath cubes and bath Such as lactate and/or 1.2-pentanediol. The lactate often is salts; skin-care preparations, e.g. skin emulsions, multi Sodium lactate. One part by weight of component c) is pref emulsions or skin oils; cosmetic personal care preparations, erably used on 4 to 100, especially 5 to 20 parts by weight of e.g. facial make-up in the form of day creams or powder the Scleroglucan. US 2009/0156563 A1 Jun. 18, 2009

0053 Specifically, amounts of component (c) relative to anoic acid, capric acid, lauric acid, isotridecanoic acid, myris component (a) are often 1 to 15% by weight, especially 4 to tic acid, palmitic acid, palmitoleic acid, Stearic acid, isos 11% by weight of a lactate Such as sodium lactate, and/or 4 to tearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic 20% by weight, especially 8 to 18% by weight, of 1.2-pen acid, linolenic acid, elaeo-Stearic acid, arachidic acid, gado tanediol, each relative to the 3-1,3-scleroglucan (a). leic acid, behenic acid and erucic acid and technical-grade 0054 Regarding end-product formulations, the skin care mixtures thereof (obtained, for example, in the pressure composition may be formulated as a wide variety of cos removal of natural fats and oils, in the reduction of aldehydes metic or pharmaceutical preparations, for example: from Roelen's oxosynthesis or in the dimerisation of unsat creams, gels, lotions, alcoholic and aqueous/alcoholic urated fatty acids) with alcohols, for example, isopropyl alco Solutions, emulsions, wax/fat compositions, Stick prepara hol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, tions such as lipsticks or deodorants, powders or oint capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl mentS. alcohol, cetyl alcohol, palmoleyl alcohol, Stearyl alcohol, 0055 in the form of liquid preparations as a W/O, O/W, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl O/W/O, W/O/W or PIT emulsion and all kinds of micro alcohol, linoyl alcohol, linolenyl alcohol, elaeostearyl alco emulsions, hol, arachidyl alcohol, gadoleyl alcohol, behenyl alcohol, 0056 in the form of liquid crystalline structures rep erucyl alcohol and brassidyl alcohol and technical-grade mix resented either by hexagonal phase, by micellar cubic tures thereof (obtained, for example, in the high-pressure phase or by lamellar phase; among lamellar liquid hydrogenation of technical-grade methyl esters based on fats crystals, there are oleosomes, hydroSomes and phos and oils or aldehydes from Roelen's oxosynthesis and as phosomes (structure built by the combination of Sur monomer fractions in the dimerisation of unsaturated fatty factants and biomimetic phospholipids), alcohols). 0057 in the form of a gel, 0068 Examples of such ester oils are isopropylmyristate, 0.058 in the form of an oil, a cream, milk or lotion, isopropylpalmitate, isopropylstearate, isopropyl isostearate, 0059 in the form of a powder, a lacquer, a tablet or isopropyloleate, n-butylstearate, n-hexyllaurate, n-decy make-up. loleate, isooctylstearate, iso-nonylstearate, isononyl 0060 in the form of a stick, isononanoate, 2-ethylhexylpalmitate, 2-hexyllaurate, 0061 in the form of a spray (spray with propellent gas 2-hexyldecylstearate, 2-octyldodecylpalmitate, oleyloleate, or pump-action spray) or an aerosol, oleylerucate, erucyloleate, erucylerucate, cetearyl octanoate, 0062 in the form of a foam, or cetyl palmitate, cetyl Stearate, cetyl oleate, cetyl behenate, 0063 in the form of a paste. cetyl acetate, myristyl myristate, myristyl behenate, myristyl 0064. As water- and oil-containing emulsions (e.g. W/O, oleate, myristyl Stearate, myristyl palmitate, myristyl lactate, O/W, O/W/O and W/O/W emulsions or microemulsions) the propylene glycol dicaprylate/caprate, Stearylheptanoate, di preparations contain, for example, from 1 to 60% by weight, SoStearyl malate, octyl hydroxy Stearate, etc. especially from 5 to 50% by weight and preferably from 10 to 35% by weight, based on the total weight of the composition, Natural or Synthetic Triglycerides Including Glyceryl Esters of at least one oil component, from 0 to 30% by weight, and Derivatives especially from 1 to 30% by weight und preferably from 4 to 20% by weight, based on the total weight of the composition, 0069 Di- or tri-glycerides, based on C-Cs fatty acids, of at least one emulsifier, from 10 to 95% by weight, based on modified by reaction with otheralcohols (caprylic/capric trig the total weight of the composition, of water, and from 0 to lyceride, wheat germ glycerides, etc.). Fatty acid esters of 88.9% by weight, especially from 1 to 50% by weight, of polyglycerin (polyglyceryl-n Such as polyglyceryl-4 caprate, further cosmetically acceptable adjuvants. polyglyceryl-2 isostearate, etc. or castor oil, hydrogenated 0065. The composition according to the present invention Vegetable oil, Sweet almond oil, wheat germ oil, sesame oil, may also contain one or one more additional compounds as hydrogenated cottonseed oil, coconut oil, avocado oil, corn described below. oil, hydrogenated castor oil, shea butter, cocoa butter, Soy bean oil, mink oil, Sunflower oil, safflower oil, macadamia Fatty Alcohols nut oil, olive oil, hydrogenated tallow, apricot kernel oil, 0066 Guerbet alcohols based on fatty alcohols having hazelnut oil, borago oil, etc. from 6 to 18, preferably from 8 to 10 carbon atoms including 0070 Waxes includingesters of long-chain acids and alco cetyl alcohol, Stearyl alcohol, cetearyl alcohol, oleyl alcohol, hols as well as compounds having wax-like properties, e.g., octyldodecanol, benzoate of C12-C15 alcohols, acetylated carnauba wax, beeswax (white or yellow), lanolin wax, can lanolin alcohol, etc. dellila wax, oZokerite, japan wax, paraffin wax, microcrys talline wax, ceresin, cetearyl esters wax, synthetic beeswax etc., or hydrophilic waxes such as Cetearyl Alcohol or partial Esters of Fatty Acids glycerides. 0067. Esters of linear C-C fatty acids with linear C-C, alcohols, esters of branched C-C-carboxylic acids with Hydrocarbon Oils: linear C-C fatty alcohols, esters of linear C-C fatty acids with branched alcohols, especially 2-ethylhexanol, esters of 0071 Mineral oil (light or heavy), petrolatum (yellow or hydroxycarboxylic acids with linear or branched C-C fatty white), microcrystalline wax, paraffinic and isoparaffinic alcohols, especially dioctyl malates, esters of linear and/or compounds, hydrogenated isoparaffinic molecules as poly branched fatty acids with polyhydric alcohols (for example decenes and polybutene, hydrogenated polyisobutene, propylene glycol, dimer diol or trimer triol) and/or Guerbet squalane, isohexadecane, isododecane and others from plant alcohols, for example caproic acid, caprylic acid, 2-ethylhex or animal origin. US 2009/0156563 A1 Jun. 18, 2009

Further Components include acids from the red alga porphyra umbilicalis, mycosporine 0072 Silicones or siloxanes (organosubstituted polysilox like amino acids (as described in WO2002039974), cis-9- anes), including siloxanes (e.g. cyclic or polymeric), Silanol octadecenedioic acid, lipoic acid, laurimino dipropiomic acid compounds or dimethiconols, Silicone elastomers & resins, tocopheryl phosphates (LDTP), microcrystalline cellulose Alkyl-Modified Siloxanes (AMS), (MCC), polycarbonates as described in WO 0341676, sterols Fluorinated or perfluorinated oils, (cholesterol, lanosterol, phytosterols), as described in Super-fatting agents, WO0341675 and linear poly-alpha-glucans as described in Pearlescent waxes, U.S. Pat. No. 6,616,935 Anti-wrinkle actives, including Sulfur-containing D and L 0076. It is furthermore possible for the cosmetic prepara amino acids, vitamin B compounds etc., tions to contain, as adjuvants, anti-foams, such as silicones, Skin lightening agents structurants, such as maleic acid, Solubilisers, such as ethyl Deodorising active ingredients, for example, antiperspirants, ene glycol, propylene glycol, glycerol or diethylene glycol, Esterase inhibitors, Antibacterial active ingredients including opacifiers, such as latex, styrene/PVP or styrene/acrylamide chitosan, phenoxyethanol, chlorhexidine gluconate, copolymers, complexing agents, such as EDTA, NTA, ala 5-chloro-2-(2,4-dichlorophenoxy)-phenol (Triclosan R), ninediacetic acid or phosphonic acids, propellants, such as Consistency regulators/thickeners—Rheology modifiers, propane/butane mixtures, NO, dimethyl ether, CO, N, or such as Natural thickeners, Mineral thickeners, Synthetic air, so-called coupler and developer components as oxidation Rheology modifiers, Phospholipid derivatives: dye precursors, reducing agents, such as thioglycolic acid and Polymers, e.g. cationic polymers such as cationic cellulose derivatives thereof, thiolactic acid, cysteamine, thiomalic derivatives, anionic, Zwitterionic, amphoteric and non-ionic acid or mercaptoethanesulfonic acid, or oxidising agents, polymers; Such as hydrogen peroxide, potassium bromate or sodium Hydrotropic agents, bromate. Perfume oils, Emulsifiers, such as O/W emulsifiers, W/O emulsifiers, Non Hydrating Agents ionic emulsifiers such as PEG modified components, Anionic 0077 glycerol, sorbitol, lactic acid, alpha-hydroxiacids, emulsifiers, Silicone emulsifiers (particularly suitable for hyaluronic acid, chitosan, glycosaminoglycans and its break W/Siemulsions); down products and Sugars especially C6 and C5 Sugars such see corresponding components published on Oct. 25, 2005 on as glucose, lactose, trehalose, and arabinose, desoxyribose, ip.com under the identifier IPCOMO00130489 D for further xylose, pyrrolidone carboxylate, oligopeptides and aminoac details. ids containing or being preferentially Alanine, Asparagine, 0073. The emulsifiers are often used in an amount of, for beta-Alanine, Citrulline Glutamic acid, Histidine Leucine example, from 1 to 30% by weight, especially from 4 to 20% Lysine, Ornithine, Phenylalanine Serine, Threonine, Valine, by weight and preferably from 5 to 10% by weight, based on the total weight of the composition. Antioxidants 0074. When formulated in O/W emulsions, the preferably amount of such emulsifier system could represent 5% to 20% 0078. The topical application could contain at least one of the oil phase. hydrophilic or lipophilic antioxidant within the concentration range from 0.001% to 10% of the total weight of the cosmetic Further Components Include: preparation. 007.9 Those antioxidants are preferably selected from the Adjuvants and Additives group containing: 0075 alpha glucosylrutin (CAS No. 130603-71-3), 2-bu 0080 tocopherol (C, Y, Y, 8 isomers) and its esters of tyloctyl o-hydroxybenzoate (CAS No. 190085-41-7), vita acids with general formulas min E (CAS No. 1406-18-4), vitamin E acetate (CAS No. 58-95-7), diethylhexyl 2.6-naphthalate, di-n-butyl adipate, H(CH)n(CHR)COOH (1) di(2-ethylhexyl)-adipate, di(2-ethylhexyl)-Succinate and disotridecyl acelaat, and also diol esters, such as ethylene CH(CH-)mcH=CH(CH)nCOOH (2) glycol dioleate, ethylene glycol diisotridecanoate, propylene 0081 where R is hydrogen atom or OH group, m, n are glycol di(2-ethylhexanoate), propylene glycol diisoStearate, integral numbers from 0 to 22 where m+n Sum is maxi propylene glycol dipelargonate, butanediol diisoStearate and mally 22. neopentylglycol dicaprylate. Esters of C-C fatty alcohols 0082 tocotrienol (C., B, Y. 8 isomers), containing one and/or Guerbetalcohols with aromatic carboxylic acids, Satu unsaturated fatty chain, and its esters of acids rated and/or unsaturated, especially benzoic acid, esters of 0.083 ascorbic acid and its esters of acids such as phos C-Cadicarboxylic acids with linear or branched alcohols phoric acid and also sodium, potassium, lithium and having from 1 to 22 carbonatoms or polyols having from 2 to magnesium salts, Ascorbyl Tetraisopalmitate, further 10 carbon atoms and from 2 to 6 hydroxy groups, or imino ester with pyrrolidoncarboxylic acid and esters of acids disuccinic acid and imiondisuccinic acid salts CAS 7408 with general formulas 20-0 or latex particles, aloe Vera, chamomile, ginko biloba, ginseng, coenzyme Q10, laminaria ochroleuca extract, mag H(CH)n(CHR)COOH (3) nolia oborata extract, melalenca alternifolia leaf oil, rubus idaeus seed oil, vaccinium macrocarpon seed oil, pumpkin CH(CH-)mcH=CH(CH)nCOOH (4) seed extract, pumpkin seed oil, grape seed extract, carnosine, 0084 where R is hydrogen atom or OH group, m, n are alpha-arbutin, madecassoside, termino-laside, tetrahydrocur integral numbers from 0 to 20 where m+n sum is maxi cuminoids (THC), mycosporines, mycosporine like amino mally 21. US 2009/0156563 A1 Jun. 18, 2009

I0085. Retinoids include all natural and/or synthetic examples of such antioxidants are amino acids (e.g. glycine, analogs of vitamin A or retinal-like compounds which histidine, tyrosine, tryptophan) and derivatives thereof, imi possess the biological activity of vitamin A in the skinas dazoles (e.g. urocanic acid) and derivatives thereof, peptides, well as the geometric isomers and stereoisomers of these Such as D.L-carnosine, D-carnosine, L-carnosine and deriva compounds. Preferred compounds are retinal, retinol tives thereof (e.g. anserine), aurothioglycose, propylthiou esters (e.g., C2-C22 alkyl esters (saturated or unsatur racil and other thiols (e.g. thioredoxin, glutathione, cysteine, ated alkyl chains) of retinal, including retinyl palmitate, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, retinyl acetate, retinyl propionate), retinal, and/or ret propyl, amyl, butyl, lauryl, palmitoyl, oleyl, linoleyl, choles inoic acid (including all trans retinoic acid and/or 13-cis teryl and glyceryl esters thereof) and also salts thereof, dilau retinoic acid) or derivatives. Other retinoids which are ryl thiodipropionate, distearyl thiodipropionate, thiodipropi useful herein are described in U.S. Pat. No. 4,677,120, onic acid and derivatives thereof (esters, ethers, peptides, issued Jun. 30, 1987 to Parish et al; U.S. Pat. No. 4,885, lipids, nucleotides, nucleosides and salts) and also Sulfox 311, issued Dec. 5, 1989 to Parish et al; U.S. Pat. No. imine compounds (e.g. buthionine Sulfoximines, homocys 5,049,584, issued Sep. 17, 1991 to Purcell et al., U.S. teine Sulfoximine, buthionine Sulfones, penta-, hexa-, hepta Pat. No. 5,124,356, issued Jun. 23, 1992 to Purcellet al. thionine Sulfoximine). Other suitable retinoids are tocopheryl-retinoate toco 0096. But also (metal) chelating agents (e.g. hydroxy fatty pherol ester of retinoic acid (trans or cis), adapalene acids, palmitic acid phytic acid, lactoferrin) and preferably 6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphtoic those disclosed in U.S. Pat. No. 5,487,884, issued Jan. 30, acid and tazarotene (ethyl 6-2-(4,4-dimethylthiochro 1996 to Bisset et al; International publications No. 91/16035 man-6-yl)-ethynylnicotinate); & No. 91/16034 from Bush et al., published Oct. 31, 1995. I0086 carotenoids such as C.-, B-, y-, and 6-carotene, Hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic lutein, Xanthophylls, Zeaxanthine, astaxanthin, violax acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, anthine, cryptoxanthine, fukoxanthine, antheraxan EDDS, EGTA and derivatives thereof, unsaturated fatty acids thine, lycopene, didehydrolycopene and tetradehydroly and derivatives thereof (e.g. linolenic acid, linoleic acid, oleic copene carotenoids acid), folic acid and derivatives thereof, coniferyl benzoate of I0087 enzymatic antioxidants such as Glutathione per benzoin resin, ferulic acid, furfurylidene glucitol, carnosine, oxidase, Catalase, Superoxide dismutase. butyl hydroxytoluene, butyl hydroxyanisole, nordihy I0088 Ubiquinone and Idebenone (hydroxydecyl droguaiaretic acid, trihydroxy-butyrophenone, uric acid and Ubiquinone), Ubiquinol and its derivatives derivatives thereof, mannose and derivatives thereof, N-3- I0089 Lipoic acid and its derivatives such as alpha-li (3,5-di-tert-butyl-4-hydroxyphenyl)propionylsulfanilic acid poic acid. . . . (and salts thereof, for example the disodium salts), Zinc and 0090 Rutinic acid and its derivatives such as C-gluco derivatives thereof (e.g. ZnO, ZnSO), selenium and deriva sylrutin, a water soluble flavonoid, rutin hydrate (vita tives thereof (e.g. selenium methionine), stilbene and deriva min P) tives thereof (e.g. stilbene oxide, trans-stilbene oxide) and the 0091. Botanical extracts such as white and green tea derivatives Suitable according to the invention (salts, esters, extracts, chicory leaf extract (Cichorium intubvbus), ethers, Sugars, nucleotides, nucleosides, peptides and lipids) Passionflower extract (Passiflora incarnata), Aspal of those mentioned active ingredients. HALS (="Hindered athus linearis extract, rosmary extract, red leaf extract of Amine Light Stabilizers') compounds may also be men Aceraceae Maple tree or of Rosaceae Chemy tree, Cur tioned; components of those latest categories, carbon orester/ cuma longa L (curcuminoids active ingredients), Leon amide bridged phenols or lactones thereof, or some sterically topodium alpinum extract, Emblica officinalis (phyllan hindered amines as disclosed in PCT patent application No. thus emblica) tree extract . . . . EP2005/055475 of Oct. 24, 2005, or published on Oct. 25, 0092. Phenolic acids such as caffeic acid, 3,4-dihydrox 2005 on ip.com under the identifier IPCOMO00130489D. yphenyl acetic acid, 3,4-dihydroxybenzoic acid. Anti-Inflammatory Agents 0093. Flavonoids and polyphenols such as flavanones Selected from the group consisting of unsubstituted fla 0097. The topical application could additionally contain at Vanones, mono-Substituted flavanones, and mixtures least one component with anti-inflammatory effect, prefer thereof chalcones selected from the group consisting of ably from 0.1% to 10% more preferably about 0.5% to about unsubstituted Chalcones, non-substituted chalcones, di 5%, of the composition, from following groups: Substituted chalcones, tri-substituted chalcones, and 0.098 Steroidal anti-inflammatory agents, including but mixture thereof flavones selected from the group con not limited to, corticosteroids such as hydrocortisone sisting of unsubstituted flavones, mono-Substituted fla and their derivatives . . . . Vones, di-substituted flavones, and mixtures thereof; one 0099 Non-steroidal anti-inflammatory agents, includ or more isoflavones; coumarins selected from the group ing but not limited to, oxicams, Salycilates, acetic acid consisting of unsubstituted coumarins, mono-Substi derivatives, fenamates, propionic acid derivatives, pyra tuted coumarins, di-substituted coumarins, and mixtures Zoles . . . thereof: flavonols, anthocyanins, catechins, proantho 0.100 Natural anti-inflammatory agents including but cyanidins (Grape seed extract). Flavonoids which are not limited to: broadly disclosed in U.S. Pat. Nos. 5,686,082 and 5,686, 0101 C.-bisabolol, allantoin, lyophilized extract of 367 can also be used. aloe Vera, panthenol, betulin, compounds of the Lico 0094) chlorogenic acid and ferulic acid. rice (Glycyrrhiza glabra) including glycyrrhetic acid, 0095. It is also possible to use a second kind of antioxi glycyrrhizic acid, and derivatives thereof (salts and dants that interrupt the photochemical reaction chain trig esters) such as sodium glycyrrhizinate, potassium gered when UV radiation penetrates the skin or hair. Typical glycyrrhizinate, ammonium glycyrrhizinate US 2009/0156563 A1 Jun. 18, 2009

0102 botulinic acid, alkaline salts thereof and salts ingredients eugenol, menthol and thymol in clove oil, mint oil of alkaline-earth metals, boswellic acid, alkaline salts and thyme oil. A natural deodorising agent of interest is the thereof and salts of alkaline-earth metals, rosemaric terpene alcohol farnesol (3.7.11-tri-methyl-2,6,10-dodec acid, alkaline salts thereof and salts of alkaline-earth atrien-1-ol), which is present in lime blossom oil. Glycerol metals monolaurate has also proved to be a bacteriostatic agent. The 0103 polynonsatured fatty acids, as linoleic amount of the additional bacteria-inhibiting agents present is (18:2nó), C.-linolenic (18:3n3), Y-linolenic (18:3n6), usually from 0.1 to 2% by weight, based on the solids content octadekanetetraenic (18:4n3), dihomo-y-linolenic of the preparations. (20:3nó), eikosantetraenic (20:4n3), arachidonic (20: 4n6), eikosanpentaenic (20:5n3) acids and esters Colourants thereof with alcohols of the general formula 0107 There may be used as colourants the substances that are Suitable and permitted for cosmetic purposes, as com where R1 and R2 are hydrogenatoms or OH group, m, piled, for example, in the publication “Kosmetische Färbe in are integral numbers from 0 to 17 where m+n sum is mittel' of the Farbstoffkommission der Deutschen Fors maximally 21; chungsgemeinschaft, Verlag Chemie, Weinheim, 1984, pages 0104 phytosterols and their polyethoxylate derivatives 81 to 106. The colourants are usually used in concentrations of the general formulas (6) and (7) below, where R is of from 0.001 to 0.1% by weight, based on the total mixture. isoalkyl or isoalkenyl group with 8-10 carbon atoms, where n is integral number from 0 to 50, especially Anti-Dandruff Agents campesterol, B3-sitosterol, Stigmasterol, cholesterol, 0108. As anti-dandruff agents there may be used, for A-5-avenasterol, A-7-avenasterol, brassicasterol, spin example, climbazole, octopiroX and Zinc pyrithione. Custom asterol and fukosterol ary film formers include, for example, chitosan, microcrys talline chitosan, quaternised chitosan, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, polymers of qua (6) ternary cellulose derivatives containing a high proportion of CH3 acrylic acid, collagen, hyaluronic acid and salts thereof and similar compounds. 0109 The active ingredients of present components a) and CH3 c) or even other actives Such as antioxidants, anti-inflamma tory agents, anti-wrinkle ingredients, skin lightening agents, etc. may be integrated in a cosmetically or dermatologically acceptable carrier system within the cosmetic end-product (cosmetic preparation). Several particulate skin care delivery systems are proposed: CH3 A Nanoemulsions and nanoparticles are mainly based on lecithin or fractionated phospholipids; 0110 nanoemulsions with particle size range of 20 CH3 nm-50 nm represented by a single layer membrane: 0.111 Nanotopes are lipid core surrounded by a mem brane composed of phospholipids and co-surfactants; stable and Small size particle (Smaller than liposomes) due to the intecalation of co-surfactant between the extending lecithin molecules 0112 Nanosomes Preservatives and Bacteria-Inhibiting Agents 0113 nanoparticles with particle size range of 100 0105 Suitable preservatives include, for example, nm -300 nm represented by a bi-layer membrane: Methyl-, Ethyl-, Propyl-, Butyl-parabens, Benzalkonium 0114 Liposomes are spherical vesicles which consist of chloride, 2-Bromo-2-nitro-propane-1,3-diol, Dehydroacetic amphiphilic lipids (predominantly phospholipids) acid, Diazolidinyl Urea, 2-Dichloro-benzyl alcohol, DMDM enclosing on aqueous core and forming one or several hydantoin, Formaldehyde solution, Methyldibromoglutani concentric bi-layers; small unilamellar vesicles (SUV), trile, Phenoxyethanol, Sodium Hydroxymethylglycinate, large unilamellar vesicles (LUV), large multilamellar Imidazolidinyl Urea, Triclosan, Silver Dihydrogen Citrate vesicles (MLV) or multivesicular vesicles (MVV). The and further substance classes listed in the following refer incorporation of the antioxidant composition could be ence: K. F. DePolo—A short textbook of cosmetology, Chap achieved into the bi-layers, into the aqueous core or ter 7, Table 7-2, 7-3, 7-4 and 7-5, p 210-219. distributed in both. 010.6 Typical examples of bacteria-inhibiting agents are B Microcapsules with particle size > 1 um based on matrix or preservatives that have a specific action against gram-positive encapsulation layer; bacteria, such as 2,4,4-trichloro-2'-hydroxydiphenyl ether, 0115 Spherical system based on a core material contain chlorhexidine (1,6-di(4-chlorophenyl-biguanido)hexane) or ing the active. The core is, then Surrounded by one or several TCC (3,4,4-trichlorocarbanilide). Silver Dihydrogen Citrate coating layers or shells. is also exhibiting good bacteria-inhibiting property. A large 0116 Polymers used to form those microcapsules include number of aromatic Substances and ethereal oils also have natural gums, cellulosic ingredients, polysaccharides, Syn antimicrobial properties. Typical examples are the active thetic polyacrylates or polyacrylamides or even polyvinyl US 2009/0156563 A1 Jun. 18, 2009 alcohol (PVA), but also lipids, inorganics (silicates/clays) and of surfactants (detergent agents) should represent from 4% to high molecular weight proteins such as gelatin, albumin . . . 50%, and preferably from 6% to 35% of the total weight of the 0117 Nylon micro-porous spheres (Orgasol range from final composition. Elf Atochem) I0131 The cosmetic detergent composition should have a 0118 Mineral fillers such as sericite surface-treated by pH from 3 to 10, and preferably adjusted between 4 and 8 with bifunctional coating; reaction between reactive fatty basic solutions such as Monoethanolamine, Diethanolamine, acid derivatives and the aqueous solution of sericite. Triethanolamine, isopropanolamine or propanediamine-1,3, 0119 Glycospheres; core based on modified starch and but also with acidic solutions such as citric acid, lactic acid, outer lipid membrane based on fatty acids and polar Sorbic acid, phosphoric acid or glycolic acid. lipids Usually cosmetic detergent products contain the following I0120 Silica shells, made of silicates, for non aqueous ingredients: and Solid end-products such as sticks, dry powders . . . . C Matrix particulate systems which entrap the active ingre (0132) Surfactants dient within the uniform core matrix; 0.133 thickeners and polymers as previously described I0121 Solid Lipid Nanoparticle (SLN) technology for emulsion end-products based only on solid lipids 0134) foam stabilizers and boosters 0.122 Nanostructured Lipid Carriers (NLC) made of 0.135 diluents such as water or polyols or other hydro blend of solid lipid and liquid lipid Eparticle size diam topic agents as previously described for emulsion end eter within the range 80 nm-1 um products I0123 Nanospheres (patent Nanosal U.S. Pat. No. 0.136 additives such as Super fatting agents, anti 6,491.902) represented by solid hydrophobic and highly wrinkle or skin lightening agents, biogenic active ingre cationic nanospheres (particle size range 10 nm to 1 um) dients as previously described for emulsion end-prod and based on solid hydrophobic matrix coated with highly cationic or bioadhesive layer lucts D Multi-walled delivery systems 0.137 pearlizers/opacifiers 0.124. They are similar to liposome structures but made 0.138 colorants as previously described for emulsion only of non-phospholipidic “membrane-mimetic' end-products amphiphiles such as oleic acid, Saturated or unsaturated fatty 0.139 perfumes as previously described for emulsion acids, long-chain soaps combined with non ionic Surfactants, end-products derivatives of polyglycerol, di-ammonium amphiphiles, cat 0140 preservatives and bacteria-inhibiting agents as ionic Surfactants, cationic amphiphiles involving aminoacid previously described for emulsion end-products residues. Sucrose fatty acid esters, aqueous mixture of anionic complexing agents (EDTA, NTA) and reducing and cationic Surfactants. 0.141 E MicroSponge technology agents 0.125 Such system is based on microscopic polymer 0142. Surfactants, such as Anionic surfactants, Non ionic based sphere that consist of myriad of interconnecting Voids Surfactants, Amphoteric or Zwitterionic Surfactants, Cationic within a non collapsible structure (non continuous shell); Surfactants, are known components, mainly as published in example are copolymer of styrene and divinylbenzene, or on Oct. 25, 2005 on ip.com under the identifier vinyl derivatives, water-swellable particles made of lactose, IPCOMO00130489D (see there for further details). cellulose and cellulose derivatives such as Unispheres from Induchem . . . . FORMULATION EXAMPLES F Silicone-based vesicles 0126 These are multi-layers vesicles similar as liposome 0143. In the following examples, the aqueous solution of structures where layers are made of polyether-modified dime Scleroglucan used contains the Scleroglucan of Sclerotium thicone (dimethicone copolyol), silicone elastomers or rolfsii, and is one of the following concentrates: blends of dimethicone crosspolymer, dimethicone/vi 0.144 a 1.0% b.w.aqueous solution of said scleroglucan nyldimethicone crosspolymer or PEG-modified dimethicone (formulation A) or crosspolymer 0145 formulation A mixed with sodium lactate to G Cyclodextrins finally contain 7.5% b.w. of sodium lactate (formulation B) or 0127 Oligomeric and cyclic carbohydrate compounds 0146 formulation A mixed with 1.2-pentanediol to containing 6 to 8 glucose units: C-, 3- and Y-cyclodextrin finally contain 12.5% b.w. of 1.2-pentanediol (formula 0128. The composition according to the present invention tion C) or may also constitute detergent compositions such as any sham 0147 formulation A, to which sodium lactate and 1,2- poo, shower-gel, foaming bath, body wash preparations with pentanediol is added, the final aqueous solution contain cleansing, washing, conditioning or scrubbing effects on skin ing 7.5% by weight of sodium lactate and 12.5% by and/or hair. weight of 1,2-pentanediol (formulation D). 0129. The cosmetic detergent composition should contain water deionised or a mix of water and acceptable cosmetic Conditioning Shampoo Solvent Such as C1-C4 alcohols (ethanol, isopropanol, ter tiobutenol, n-butanol) or glycols such as propylene glycol, 0.148. The requirements of a shampoo are to clean hair and glycol ethers . . . . Scalp of soils and dirt; ingredients must be safe (low toxicol 0130. The water content should be between 40% and 95% ogy, low sensitization and low skin/eye irritation potential) of the total weight of the final composition. The total amount and the detergents must present low Substantivity. US 2009/0156563 A1 Jun. 18, 2009

014.9 The main ingredients in this application fields are: -continued Primary Surfactants Ingredients 0150 Alkyl Sulfates, such as Ammonium Lauryl Sulfate, Decyl Oleate TEALauryl Sulfate, Sodium Lauryl Sulfate Ammonium Lau Polyguaternium-7 reth Sulfate, Sodium Laureth Sulfate, Sodium C14-16 Olefin Potassium Citrate Sulfonate; Iminodisuccinate PEG-40 Hydrogenated Castor Oil Sulfo Succinates, such as Disodium monlaureth Sulfo Succi Polyether-1 nate, Disodium monolauramido MEA sulfosuccinate, Diso Aqueous Scleroglucan formulation dium monoleamido PEG-2 sulfosuccinate; Perfume N-Acyl Sarcosinates, such as Sodium Cocoyl Sarcosinate, Preservative C.S Sodium Lauroyl Sarcosinate; Water deionized Qsp 100 N-Acyl Methyltaurates, such as Sodium N-methyl Cocoyl Taurate; Amphoterics, such as Sodium Cocoamphoacetate, Sodium Pearlized Mild Body Wash Cocoamphodiacetate, Sodium Cocoamphopropionate. Secondary Surfactants O155 0151. Betaines, such as Cocamidopropyl betaine, Oleami dopropyl betaine, IsoStearamidopropyl betaine; 0152 Amides, such as Lauramide DEA, Cocamide DEA; Ingredients 0153. Foam Stabilizers, such as Lauramide DEA, Cocam Sodium Laureth Sulfate 15% ide DEA, Cocamine Oxide; pH adjusting agents, such as Cocoyl Isethionate 4%-6% Sodium Lauroamphoacetate 4%-6% Citric, Lactic, Sorbic, Phosphoric or Glycolic acids. Sodium Xylene Sulfonate 190-5% Sodium Methyl Cocoyl Taurate 190-5% Acrylates Crosspolymer 1.5% Water deionized 14.5% ngredients Dimethiconol and TEA 4% Dodecylbenzenesulfonate Primary surfactants (listed S96-10% Sodium Cocoamphoacetate 296 previously) Polyguaternium-7 296 Secondary surfactants (listed 5%-15% Water deionized 59 previously) Sodium Hydroxide (18% solution) O.05% Foam Stabilizers (listed previously) O%-5% Guar Hydroxypropyl trimonium O.15% Water deionized 40%-70% Chloride Actives O%-10% Citric acid (50% solution) Conditioners Water deionized Refatting agents Mica and Titanium Dioxide Moisturizing agents Aqueous Scleroglucan formulation Thickeners/Rheology mofifiers O%-3% Perfume Humectants O%-29/o Citric acid (50% solution) Aqueous Scleroglucan formulation O.1%-5% Preservative PH adjusting agents O%-1.9/o Preservatives O.05%-1.96 Perfume oils O.1%-1% Antioxidants O.05%-0.20% Chelating Agents (EDTA) O%-O.2% Clear Shampoo Opascifying agents O%-29/o 0156

Shower-Gel Ingredients 0154) Sodium Lauryl Sulfate 196 Sodium Polyoxyethylene lauryl 12% sulfate Lauroamidopropyl betaine 196 Ingredients POE (16) lauryl ether 196 Glyceryl monoisodecyl ether O.S9/o Sodium Laureth Sulfate 15%-18% Cationized cellulose O.S9/o Lauryl Glucoside 4%-6% Polyvinyl Alcohol O.2% Decyl Glucoside 4%-6% Glycerin 10% Cocamidopropyl Betaine 190-5% Tocopherol Acetate O.24% Sodium Cocoamphoacetate O%-29/o Sodium Sulfate 3% PEG-200 Glyceryl Palmate O%-29/o Aqueous Scleroglucan formulation O.1%-5% PEG-1SO 4%-6% Perfume O.1% PEG-240 8%-10% Sodium Hydroxide qs pH = 7 PEG-220 5%-6% Water deionized Qsp 100 Triethyl Citrate 296-99/o Glyceryl Mono Oleate 190-290 US 2009/0156563 A1 Jun. 18, 2009 11

Clear Bath Gel with Suspended Beads (0163) 19 mg Boric acid 0.164 0.04 mg. Opthalmological preservative (Thiomer sal) Ingredients 0.165 Water for injection purposes to 1.00 ml. Sodium Laureth Sulfate (28% 30% Oral Care Preparation solution) Acrylates Crosspolymer (30% 10% 0166 The composition according to the present invention solution) may also constitute an oral care preparation, e.g. a dental gel. Propylene Glycol 2% a denture fixation aid, mouth rinse, or a toothpaste; a mucosal Sodium Hydroxide (18% solution) 1.9% Disodium EDTA O.1% lubricant formulation such as a vaginal cream or gel; or an Benzophenone-4 O.02% opthalmological preparation e.g. selected from eye drops, Cocamidopropyl Betaine (35% 4% artificial tear or saliva formulations etc., in which the glucan solution) component a) optionally in combination with component c) Polysorbate 20 O.8% White beads 190 may perform one or more of the following functions: Aqueous Scleroglucan formulation O.1%-5% i) effect lubrication of dry mucosae: Perfume O.6% ii) effect thickening of liquid preparations; Citric acid (50% solution) O.6% Preservative 190 iii) effect retention of active ingredients by formation offilms Water deionized Qsp 100 on mucosal Surfaces; and iv) effect an improvement in the dispersion of other compo nents in the composition. 0167. The composition according to the present invention Opthalmological Preparation may also be used as e.g. a dental gel, a denture fixation aid, 0157. When the B-1,3-scleroglucan is used in an opthal mouth rinse, or a tooth paste. mological preparation, it may be used together with other 0168 Such compositions are dealing to treat the hard and soft tissues surfaces of the oral cavity. The oral care and components such as: hygiene contribute to maintain prophylactic, therapeutic and a) opthalmological active ingredients e.g. Gentamicin Sul cosmetic benefits that include reduction in caries, in plaque, phate, Lomefloxacin hydrochloride, Chloramphenicol, in gingivitis and in tartar, treating hypersensitivity; freshen Sodium Diclofenac, Potassium Diclofenac, Dexamethason ing breath; whitening teeth and/or removing stains; reminer di-sodium phosphate, Naphazolin nitrate, Tetryzolin hydro alising teeth and the like. chloride, Antazolin hydrochloride, Antazolin sulphate, Pilo 0169. Several product forms are proposed such as denti carpin chloride, Vitamin A-palmitate and Zinc sulphate: frices or toothpastes, mouthwashes, chewing gums contain ing for example teeth whitening actives, anti-caries actives, b) opthalmological buffers such as boric acid, borax, acetic breath freshening.... All those actives can be encapsulated by acid, Sodium acetate, phosphoric acid, Sodium dihydrogen an encapsulating material that protects them from the other phosphate, disodium hydrogen phosphate, sodium phos ingredients and also from environment agressions; encapsu phate, Trometamol, citric acid and Sodium citrate; lating materials were already described in previous chapters. c) opthalmological preservatives such as benzyl alkylammo Nevertheless, we could mention Cyclodextrin, gum arabic, nium chloride, benzoxonium chloride, chlorhexidine diglu gelatin, casein, albumin, fibrinogen, Xanthan gum, haemoglo conate, chlorobutanol, phenylethyl alcohol and Thiomersal; bin, Soluble collagen peptides, sodium alginate, carboxym ethyl cellulose, carrageenan, plyvinylpyrrolidone and similar d) Solvents such as ethanol, glycerol, polyethylene glycol and natural or synthetic polymeric materials. Typically, the water or mixtures thereof; encapsulated active will comprise from 0.01% to 10% of the e) solution aids such as Cremophor EL, Cremophor RH, whole oral composition. Oral care products can contain a Tween 20 and Tween 80: variety of optional components suitable for rendering Such f) isotonising agents such as sodium chloride, mannitol and composition more cosmetically acceptable: sorbitol, A-organic Surface active agents such as detersive material which imparts to the composition detersive and foaming g) chelate formers such as disodium EDTA; properties; e.g. h) antioxidants such as C-tocopherol acetate, ascorbic acid, 0170 Anionic surface active agents such as water N-acetyl-cystine, Sodium bisulphite, Sodium thiosulphate Soluble salts of higher fatty acid monoglyceride mono and propyl gallate; and Sulphates, water soluble salts of higher alkyl Sulphates, i) viscosity-increasing compounds Such as methylhydrox water soluble salts of alkyl aryl sulphonates, olefinsul ypropyl cellulose, saccharose, Carbopol 934P. Carbopol 940, fonates (olefin group contains 12-21 carbon atoms), Carbopol980 and Polaxomer F127. alkylsulphoacetates, higher fatty acid ester of 1,2-dihy 0158 An aqueous opthalmological preparation may be droxy propane Sulphonates, acylamino acid and salts. . formulated e.g. from the following ingredients: ... as described in previous chapters. 0159 100 mg of a scleroglucan formulation A-D (see 0171 Nonionic surface active agents as described in above formulation examples) previous chapters and more especially the esters cat egory. 0160 1 mg Sodium Diclofenac 0172 Cationic surface active agents as described in pre 0.161 50 mg Solution aid (Cremophor EL) vious chapters and more especially the quaternized imi 0162 6 mg Opthalmological buffer (Trometamol) dazole derivatives, the tetraalkyl ammonium salts. US 2009/0156563 A1 Jun. 18, 2009

B—thickeners and Viscosity modifiers, such as 0183 Anti tartar agents; 0173 natural thickeners as described in previous chap 0.184 pyrophosphates which include pyrophosphate ters salts, dialkali metal pyrophosphate salts, tetra-alkali 0.174 block polymers of ethylene oxide and propylene metal pyrophosphate salts and mixtures thereof. Diso oxide, and other polymers as described in previous chap dium dihydrogen pyrophosphate (Na2H2P2O7), tetra ters sodium pyrophosphate (Na4P2O7) and tetrapotassium 0.175 silica and silica derivatives as described in previ pyrophosphate (K4P2O7); detailed description in Kirk ous chapters. & Othermer, Encylopeadia of Chemical Technology,3" Ed., vol. 17, 1982. C—pH adjusting and buffering agents, such as 0185. Polyphosphates; detailed description in U.S. Pat. 0176 Citric acid, succinic acid, phosphoric acid, sodium No. 4,590,066, Parran & Sakkab, May 20, 1986. hydroxide, Sodium carbonate. 0186 Polyacrylates and other polycarboxylates: D—Flavouring agents, such as detailed description in U.S. Pat. No. 3,429,963, Shed 0177. Oil of peppermint, Sassafras, cassia, clove bud oil, lovsky, Feb. 25, 1969 and U.S. Pat. No. 4,661,341, Bene menthol, anethole, thymol, methyl salicylate, eucalyptol, dict & Sunberg, Apr. 28, 1987. 1-menthyl acetate, sage, eugenol, parsely oil, Oxanone, oil of 0187 Polyepoxysuccinates; detailed description in wintergreen, alpha-irisone, oil of spearmint, marjoram, U.S. Pat. No. 4,846,650, Benedict & Sunberg, Jul. 11, lemon, orange, propenyl guaethol, cinnamon, and mixtures 1989. thereof. 0188 Polyphosphonates; detailed description in U.S. E—Humectant material. Such as Pat. No. 4,877,603, Degenhardt & Kozikowski, Oct. 31, 0.178 Glycerin, sorbitol, propylene glycol, xylitol, lac 1989. tilol, but also ethyl alcohol, mineral oil, corn Syrup, glucose 0189 Preferred anti tartar agents are the linear “glassy' and inert Sugars, glycols, honey. polyphosphates having the formula: 0179 The compositions of the invention usually contain a cosmetically or pharmaceutically acceptable carrier and/or further components or actives known for the purpose; for wherein X is sodium, potassium, or hydrogen and naverages example flavours, colorants, Sweeteners etc., components from about 6 to about 125. useful for oral care compositions are, for example, as men 0.190 Anti-plaque agents; substances that inhibit the tioned in JP-A-2001 031541 and WO 99/32073. accumulation of bacterial deposits on the surfaces of the oral cavity 0191 Examples include xylitol and other anti-microbial Examples for Oral Care Actives are: agents as described in previous chapters. 0180 Teeth colour modifying Substances; 0.192 Fluoride ion source: well known as anticaries 0181 particles that when applied on the teeth surface agents, such as modify the surface in terms of absorption and/or reflec 0193 Alkali metal monofluorophosphates that include tion of light. These include pigments colourants such as Sodium monofluorophosphate, lithium monofluoro inorganic white pigments, inorganic coloured pigments, phosphate, potassium monofluorophosphate, ammo pearling agents, filler powders and the like (JP Kokai nium monofluorophosphate. patent application No. 9 (1997)-100215, publish. Apr. 0194 Alkali metal monofluoropolyphosphates such as 15, 1997); specific examples are selected from talc, Na4P2O9F, K4P3O9F, (NH4)P3O9F, Na3 KP3O9F, mica, magnesium carbonate, calcium carbonate, mag (NH4)NaP3O9F and Li4P3O9F. nesium silicate, aluminium magnesium carbonate, 0.195 Preferred fluoride ion sources include sodium fluo silica, titanium dioxide, Zinc oxide, red iron oxide, ride, potassium fluoride, Stannous fluoride, ammonium fluo brown iron oxide, yellow iron oxide, black iron oxide, ride and mixtures thereof. The levels of those agents are ferric ammonium ferrocyanide, manganese violet, ultra generally used in the range of about 50 ppm to 10 000 ppm marine nylon powder, polyethylene powder, methacry within the oral care composition. late powder, polystyrene powder, silk powder, crystal 0.196 Anti-microbial agents; such as described in pre line cellulose, starch, titanated mica, iron oxide titanated vious chapters; mica, bismuth oxychloride, and mixtures thereof. The 0.197 especially for cosmetic/skin care applications, levels of those particles are generally used in the range of preferably, 5-chlor-2-(2,4-dichlorophenoxy)-phenol about 0.05% to about 20%, by weight, of the oral care (Triclosan), Silver Dihydrogen Citrate, Phthalic acid composition. and its salts, alexidine, hexetidine, sanguinarine, benza 0182 materials that remove or bleach intrinsic or Ikonium chloride, salicylamilide, domiphen bromide, extrinsic stains on or in teeth Surfaces. These include cetylpyridinium chloride, tetradecylpyridinium chlo peroxides, metal chlorites, perborates, percarbonates, ride, N-tetradecyl-4-ethylpyridinium chloride, peroxyacids, perSulphates, and combinations thereof. octenifine, delmopinol, octapinol and other piperidine Suitable peroxide compounds include hydrogen peroX derivatives, nicin preparations, Zinc? stannous ion ide, urea peroxide, calcium peroxide, carbamide peroX agents, essential oils including thymol, geraniol, carvac ide and mixtures thereof. Suitable metal chlorites rol, citral, hinokitiol, eucalyptol, catechol and mixtures include calcium chlorite, barium chlorite, magnesium thereof. For compositions for contact with the mucosa, chlorite, lithium chlorite, sodium chlorite and potassium or oral compositions, see above. chlorite. The levels of those agents are generally used in 0198 Nutrients the range of about 0.1% to 30%, by weight, of the oral 0199 minerals include calcium, phosphorus, fluoride, care composition. Zinc, manganese, potassium and mixtures thereof, US 2009/0156563 A1 Jun. 18, 2009 13

0200 vitamins include vit. C and D, thiamine, ribofla vin, calcium pantothenate, niacin, folic acid, nicotina -continued mide, pyridoxine, cyanocobalamin, bioflavonoids and mixtures thereof, Ingredients 0201 aminoacids include but not limited to L-tryp Sodium Aluminosilicate tophane, L-lysine, methionine, threonine, levocarnitine, Silicates derivative L-carnitine and mixtures thereof. Sodium monofluorophosphate Titanium Dioxide (opacifier) 0202 Antoxidants include those which have been Sodium Saccharinate described in previous chapters. Flavour 0203 Dentifrices/toothpastes, which are of special impor Stannous fluoride Colorants tance in oral care applications, often contain: Preservative 0204 thickeners/binders from about 0.5% to about Water deionized 30%, 0205 humectants from about 5% to about 75%, 0206 flavouring agents from about 0.1% to about 5%, 0214) Mouthwashes/mouthrinses are also of importance 0207 surfactants from about 0.01% to about 6%, in oral care applications. They represent aqueous-based for (0208 buffering agents from about 0.02% to about 10%, mulation where the active ingredients are at lower concentra (0209 preservatives from about 0.01% to about 2%, tion than toothpastes/dentifrices, and without polishing/abra 0210 water deionized from about 4% to about 60%. sive agents and no thickeners. 0211 Such specific product form needs to provide a good cleaning effect via particulate abrasives and polishing agents Mouthwash 1 Such as silicas, aluminas, calcium carbonates, dicalcium phosphates, calcium pyrophosphates, hydroxy apatites, tri 0215 methaphosphates, insoluble hexametaphosphates, and in amount between 3% and 60%. Ingredients Opaque Silica-Based Dentifrice Sodium Saccharinate O.05% 0212 PEG-40 hydrogenated castor oil O.4% Ethanol (96%) 5.3% Aqueous Scleroglucan formulation O.1%-5% Sodium benzoate O.25% Flavouring oil O.2% Ingredients Cetylpyridinum Chloride O.05% Hydro-glycolic botanical extract &1% Sodium Lauryl Sulfate 1.5-2.5% Water deionized Qsp 100 Sodium Carboxymethyl cellulose or O.7-190 Xanthan gum Sorbitol (70%) 45% Abrasive silica 10% Thickening silica 8-10% Mouthwash 2 PEG 1500 59% Titanium Dioxide (opacifier) 190 0216 Sodium Saccharinate qS Flavour &1.5% Aqueous Scleroglucan formulation O.1%-5% Colorants qS Therapeutic agents qS Ingredients Preservative &1% Sodium Saccharinate (10%) O.8% Water deionized Qsp 100 Menthyl lactate and PPG-26 Buteth-26 59% and PEG-40 hydrogenated castor oil Sorbitol (70%) 11.5% Chlorhexidine O.3% Translucent or Transparent Dentifrices Flavouring oil &1% Glycerin 23% 0213 often use porous e.g., silica Xerogel that possess Aqueous Scleroglucan formulation O.1%-5% extremely high cleansing and polishing ability without harm Alcohol (95%) 20% fully abrading the teeth enamel Surface, synthetic amorphous Water deionized Qsp 100 complex salts of aluminosilicates (as described by Tamela “Chemistry of the surface and the activity of Alumina-Silica 0217. The composition according to the present invention cracking catalyst Discussions of the Faraday Society No. 8 p may also be used as a water-based human tissue/personal 270-279 (1950)) lubricant Such as mucosal lubricant gels, fluids or creams, feminine hygiene products and contain for example: A water-soluble thickeners/rheology modifiers (as described Ingredients in previous chapters) Most preferable are: modified natural gums such as cellulose Sodium N-Lauroyl Sarcosinate 2% Glycerin 30% derivatives (methylcellulose, hydroxypropyl cellulose, Sorbitol (70%) 33% hydroxyethyl cellulose, sodium carboxymethyl cellulose, Aqueous Scleroglucan formulation O.1%-5% hydroxyethylmethyl cellulose); natural gums such as arabic, align, guar, tragacanth, pectin, alginic acid and salts, dextran US 2009/0156563 A1 Jun. 18, 2009 and Xanthan gums; synthetic gums' Such as polyvinyl alco hol, polyacrylic acid and polyvinyl pyrrolidone. -continued B high molecular weight (MW) polyethylene oxides 0218. Most preferable are ethylene oxides with MW from Ingredients 900 000 to 4 000 000 in concentration from about 2.5% Preservative O.3% downward to about 0.5%. Water deioniz. QSp Sodium laurylsulfate 1.5% Chumectant polyols that exhibit a very high degree of lubric Propylene glycol 3% ity and also act as a tissue conditioner Such as glycerol, Aloe veragel 9% diglycerol, propylene glycol, dipropylene glycol, Sorbitol and Aqueous Scleroglucan formulation O.1%-5% available poyols made by the hydrogenation of the higher Sorbitol 196 sugars or starches from about 3 to 12% of the lubricating Allantoin 2.5% Polyethylene oxides of MW < 100 000 10%-15% composition. Xanthan gum O.S90 Danti-inflammatory agents (as described in previous chap Coconut flavor O.9% ters) and/or healing/soothing agents such as aloe Vera, lano lin, allantoin, alpha-bisabolo, panthenol, Nordihydroguai aretic Acid (NDGA). 0224 For feminine hygiene personal cleaning/cleansing E anti-tack or anti-sticking agents such as polyethoxylated products, specific Surface active agents that provide solubi Sorbitan monoalkanoates (lauryl, myristyl, palmityl, oleyl, lizing and detergent properties are necessary Such as: stearyl esters of polyethoxylated sorbitans, where the ethoxyl A Specific anionic Surfactants, e.g. groups may range from about 15 to 30 in chain length), 0225 alkanoyl sarcosinates corresponding to the for glycerol monoalkanoates. mula RCON(CH3)CH2CH2COOM wherein R is alkyl F Surfactants and wetting agents (as described in previous or alkenyl of about C10 to C20, and M is a water-soluble chapters) cation Such as ammonium, Sodium, potassium and 0219 Most preferable are: anionic surfactants such as sul alkanolamine; for example, sodium lauroyl sarcosinate, fates (sodium lauryl Sulfate, Zinc coceth Sulfate), acylamino Sodium cocoyl sarcosinate, ammonium lauroyl sarcosi acid and salts (sodium cocoylglutamate, disodium capryloyl nate and sodium myristoyl sarcosinate, TEA salts of sarcosinates; glutamate, sodium lauroyl sarcosinate), mild/anti-irritant Sur 0226 taurates having between C8 and C16; for factants such as acylamphoacetates, Sulfo Succinates. example, ammonium, Sodium, potassium and alkanola G preservatives (as described in previous chapters) mine salts of lauroyl methyl taurate, myristoyl methyl 0220 Most preferable are: propyl and methyl parabens, taurate or cocoyl methyl taurate; silver dihydrogenated silver, triclosan. Also of interest are 0227 lactylates having between C8 to C16; for bacteria inhibiting agents (as described in previous chapters), example, ammonium, Sodium, potassium and alkanola fungicidal and fungistatic agents. mine salts of lauroyl lactylate, cocoyl lactylate, caproyl 0221 Representative Formulations are Given by the Fol lactylate; lowing Examples; 0228 glutamates having between C8 to C16; for example, ammonium, Sodium, potassium and alkanola Fluid Lubricant Model mine salts of lauroyl glutamate, myristoyl glutamate, 0222 cocoylglutamate. B Specific amphoteric Surfactants, e.g. 0229 betaines which are derived from acylamidopro pyl dimethylamine; alkyl betaines, amidoalkyl betaines, Ingredients phosphobetaines, pyrophosphobetaines, cocamidopro Polyethylene oxides of MW < 4000 000 O.S90 to 2.5% pyl betaines and mixtures thereof, Polyethylene oxides of MW < 100 000 5% to 10% 0230 amphocarboxylates, Humectants 5% to 10% 0231 amidoalkyl Sultaines, Aqueous Scleroglucan formulation O.1%-5% 0232 amphophosphates, Preservatives O.2% to 1% water-soluble thickeners, rheology &O.1% 0233 carboxyalkyl alkyl polyamines, modifiers 0234 lauroamphodiacetates. Water deionized Qsp 100 C Specific nonionic Surfactants, such as 0235 polyoxyethylene derivatives of polyol esters, wherein the fatty acid part is containing C8 to C22 and Personal Lubricant the polyol is selected from Sorbitol, Sorbitan, glucose, C.-methylglucoside, polyglucose, glycerin, pentaeryth 0223 ritol and mixtures thereof. Typical examples are PEG-80 sorbitan laurate, polysorbate 20, PEG-80 sorbitan lau rate (PEG stands for polyethyleneglycol). Ingredients Feminine Hygiene and lubricating Lotion Lubricating agents 5%-15% Lanolin anhydrous 8% Sweet almond oil 59 Ingredients Coconut oil 10.75% Cetyl alcohol O.S90 Lubricating agents 5%-15% Mineral oil 196 Lanolin anhydrous 8% US 2009/0156563 A1 Jun. 18, 2009 15

skin test area. For the purpose of comparison, a control -continued experiment is conducted using a placebo containing none of Ingredients the Scleroglucan formulations. 0240. The results obtained show a good reduction of skin Sweet almond oil 59 Coconut oil 10.75% roughness (relative to untreated skin) both lotions containing Cetyl alcohol O.S90 0.005% by weight or 0.05% by weight of the B-1,3-sclero Mineral oil 196 glucan formulations, while the skin Stickiness is reduced in Preservative O.3% formulations containing the lower amount of Scleroglucan. Water deioniz. QSp Sodium laurylsulfate 1.5% Propylene glycol 3% Example 2 Aqueous Scleroglucan formulation O.1%-5% Aloe veragel 9% Sorbitol 196 0241 The skin moisturising activity of the B-1,3-sclero Allantoin 2.5% glucan (0.01% or 0.05%) dissolved in water is investigated Polyethylene oxides of MW < 100 000 10%-15% Xanthan gum O.S90 under defined climatic conditions (22° C. and 60% relative Coconut flavor O.9% humidity). Test Solutions are obtained using formulations A-D, each containing 1% by weight of active, by diluting to obtain aqueous solutions containing 0.05% or 0.01% by Feminine Hygiene Cleansing Formula weight of the B-1,3-scleroglucan (formulation A), or 0.05% or 0.01% by weight of active mixture (formulations B, C, D). 0236 0242. The test solutions are applied to the forearm. Skin moisture ratings are determined prior to application of the test Solution and in regular intervals of 2 hours after application. Ingredients The determinations are conducted using a Corneometer Chamomile extract 1.5% (model CM820 Courage & Khazuka, Germany). The per Lactic acid (80% solution) O.OOS9/o centage increase of skin moisture in the treated skin area Surfactant (as previously described) 1.5%-10% relative to untreated skin is calculated. The number of volun Solubilizer (as previously described) O.S96-1.5% teers used is 10. Aqueous Scleroglucan formulation O.1%-5% Preservative O.2%-1% 0243 The increase in skin moisture, 1 hour after applica Water deioniz. 90%-95% tion of formulation A, is compared to the increase in skin Propylene glycol O.8% Fragrance qS moisture 1 hour after application of formulation B, C or D for each of the concentrations. 0237. The cosmetic or pharmaceutic composition of the 0244 Preparations containing formulations B, C and D invention may also comprise further components which are show an effect Superior over the preparation containing for known to perform a useful function in a cosmetic composi mulation A. tion. Examples of such further components include, e.g., UV absorbers such as an oxanilide, a triazine or triazole. The Example 3 following examples illustrate the effect of scleroglucan which are described and claimed in the invention, or of the combi 0245 Incorporation of 0.05% Scleroglucan (dry weight) nation glucan or Scleroglucan with bactericide which are into 2.0% of a mixture of glyceryl Stearate and PEG-100 described and claimed in the invention. All percentages are by stearate (Arlacel(R) 165), 1.5% cetearyl alcohol (Lanette RO), weight unless otherwise specified. Qsp stands for an amount 1.0% of cetearyl alcohol and Ceteareth-20 (Emulgade(R) of carrier (such as water) to be added to reach 100%; qs stands 1000NI), 4.5% Dicaprylyl Ether (CetiolR OE), 3.0% ethyl for an amount of ingredient adjustable within a wider range to hexyl stearate (Crodamol(ROS), 1.5% Cas-alkyl-benzoate meet product specifications, e.g. 0-5% b.w.. or 0.01-3% b.w. (Tegesoft(R) TN), 1.5% propylene glycol, 0.1% disodium Example 1 EDTA, 0.8% of a mixture of sodium acrylate copolymer, mineral oil and PPG-1 Trideceth-6 (SALCARE(R) SC91),3% 0238 An aqueous lotion for the treatment of skin rough of Cyclomethicone (DC 345 fluid), 0.375% lactic acid%ad ness is formulated from an aqueous emulsion containing 10% 100% water increases the “silicone-like touch by 20% and by weight of glyceryl stearate and either 0.005% or 0.05% or reduces “waxy” feeling by 15% (average values measured by 0.5% by weight of B-1,3-scleroglucan (using formulations a panel of 10 trained specialists for psychosensory assess A-D described further above). ment of topical cosmetic products). 0239. The determination of skin roughness is conducted according to German standard DIN 4768ff. The roughness of the skin is determined by taking silicone-based skin impres Example 4 sions and then measuring the Surface profile of the impres sions, using computer-aided profilometry. The skin rough 0246 Incorporation of 0.02% Scleroglucan (dry weight) ness is calculated from the multiple measuring points (100 into formulation of 3% acrylates/Beneth-25 methacrylate points per square millimeter). The number of Volunteers used copolymer (TINOVIS(RGTC), 2% Dimethicone Copolyol is 10. The determination of skin roughness is conducted both (Abil R. B88183), 0.7% of preservative composition (Germa prior to application of the test lotion and 8 hours after appli ben(RII), 0.25% of 1,2-pentanediol, ad 100% water, increases cation of the test lotion. The skin of the forearm is used as the “silicone-like touch by 10% and reduces “waxy” feeling by US 2009/0156563 A1 Jun. 18, 2009

10% (average values measured by a panel of 10 trained spe cialists for psychosensory assessment of topical cosmetic -continued products). Formulation

Example 5 A. B 0247 Incorporation of 0.02% Scleroglucan (dry weight) Percent Percent into formulation of 3% acrylates/Beneth-25 methacrylate Ingredients by weight by weight copolymer (TINOVIS(RGTC), 2% Dimethicone Copolyol P-chitosan O.O2 O.O2 (Abil R. B88183), 0.7% of preservative composition (Germa Scleroglucan' O.O2 O.O2 ben(R) II), ad 100% water, increases “silicone-like' touch and Chlorohexidine O.2 reduces “waxy” feeling on skin (determined by a panel of 10 'active agent of Tinocare GL, Ciba Specialty Chemicals trained specialists for psychosensory assessment of topical ‘’’phosphonochitosan (Tinocare CP, Ciba Specialty Chemicals) cosmetic products). 0251 Mouth wash. A provides a distinctly better prophy EXAMPLE 6 laxis against bacterial plaque than mouth wash B. Preparation of a Toothpaste Example 8 0248. The Following Components are Mixed: Measurement of the Adsorption and Desorption of Microorganisms 0252 a. Adsorption Formulation: (0253 Bacteria: S. mutans (ZIB6008); S. mitis (KL-stab.); A. B S. anguinosus (ZIB6006) and S. sanguis (ZIB6010) are plated Ingredients % by weight % by weight out anaerobically on BA plates and incubated. One colony Distilled water ad 100 ad 100 each is allowed to grow to a density of about 0.5 ODo in D-glucitol 40.O 40.O Todd-Hewitt broth as stock solution. Zeodent 113 1O.O 1O.O 0254 50 mg of hydroxylapatite pearls (HA: Macro-Prep glycerol 2O.O 2O.O Ceramic Hydroxylapatite, 80 micron, of BioRad) are washed tetrasodium pyrophosphate 12.0 12.0 disodium pyrophosphate 3.40 340 once with 1 ml of sterile HO and three times with 1 ml of Sodium lauryl Sulfate 1.37 1.37 absorption buffer sterilised by filtration (5 mM KCL, 1 mM aromatics 1.35 1.35 CC1; 0.1 mM MgCl; 1 mM KHPO, pH 7.2) (cf. Berry & PEG-6 1.33 1.33 Siragusa (1997); Appl. Environ. Microbiol. 63,4069-4074).2 Sodium carboxymethylcellulose 1.OO 1.OO sodium fluoride O.SO OSO ml of the bacterial solution are centrifuged (10,000 rpm, 5 acrylic acid homopolymer O.20 O.2O min) and washed twice with adsorption buffer and are then Saccharin sodium O.20 O.2O resuspended in 1 ml of adsorption buffer containing 0.0001 titanium dioxide O16 O16 1% of the Scleroglucanused in example 7 and 0.0001%–0.3% P-chitosan O.O3 O.O3 and/or Scleroglucan' O.O3 O.O3 of Triclosan and as controls in absorption buffer alone and in Triclosan O.30 absorption buffer containing Glucan or Triclosan only (see FD&C Blau CI 42090 (No. 1, 1% sol.) O.O3 O.O3 table below). These solutions are left for 10 min at 37° C. and then combined with the hydroxylapatite pearls suspended in 'active agent of Tinocare GL, Ciba Specialty Chemicals 1 ml of adsorption buffer and incubated, with slight shaking, 0249 Toothpaste A is distinctly more effective against for 30 min at 37° C. After the HA pearls have settled, the bacterial plaque than toothpaste B. supernatant is removed and replaced with 0.5 ml absorption buffer containing 0.05% Tween-80. HA pearls are then incu Example 7 bated in the cold and under occasional vortexing. After 15 min 4.5 ml absorption buffer are added, HA-pearls are allowed to Preparation of a Mouth Wash sediment and the Supernatant is plated accordingly on BA 0250. The Following Components are Mixed: plates and incubated. The results are shown in the following table; compositions of the invention are marked with an aster isk (*).

Formulation TABLE a

A. B Adsorption of microorganisms in presence of Scleroglucan (S) Percent Percent and/or Tricosan (T): No. of colonies Ingredients by weight by weight agent in liquid S. militans S. mitis S. anguinostis S. Sanguis Distilled water ad 100 ad 100 ethanol 1O.OO 1O.OO Ole glycerol 1O.OO 1O.OO 0.0001% S, 0.0001% PEO-PPO-PEO block polymer 2.OO 2.00 tetrasodium pyrophosphate 1...SO 1...SO O.OOO2% S aromatics 1.35 1.35 disodium pyrophosphate OSO OSO 0.001% S, 0.0003% sodium fluoride OSO OSO Saccharin sodium O.3 O.3 O.OO13% S US 2009/0156563 A1 Jun. 18, 2009 17

TABLE a-continued TABLE b-continued Adsorption of microorganisms in presence of Scleroglucan (S) Desorption of microorganisms in presence of Scleroglucan (S) and/or Tricosan (T): No. of colonies and/or Tricosan (T): No. of colonies agent in liquid S. militans S. mitis S. anguinostis S. Sanguis agent in liquid S. militans S. mitis S. anguinostis S. Sanguis O.OO13%T O.OO13% S 0.01% S, 0.003% T. O.OO13%T O.O13% S 0.01% S, 0.003% T. O.O13%T O.O13% S 0.1% S, 0.03% T. O.O13%. T O.13% S 0.1% S, 0.03% T. O.13% T 0.13% S 0.13% T 0255 Considerably fewer colonies of S. mutans, S. mitis, S. anguinosus; and S. sanguis formed in the dilutions con 0258 Considerably fewer colonies of any formed when taining both Glucan and Triclosan than in the appropriate combining Glucan and Triclosan than in the appropriate dilu dilutions of Glucan or Triclosan alone and even fewer than in tions of Glucan or Triclosan alone and even fewer than in the the untreated control. untreated control. b. Desorption Example 9 0256 Bacteria: S. mutans (ZIB6008); S. mitis (KL-stab.); S. anguinosus (ZIB6006) and S. sanguis (ZIB6010) are plated (0259 Bacteria: S. mutans (ZIB6008); S. mitis (KL-stab.); out anaerobically on BA plates and incubated. One colony S. anguinosus (ZIB6006), S. sobrinus (OMZ 176) and S. each is allowed to grow to a density of about 0.5 ODo in sanguis (ZIB6010) are plated out on BA plates. Stock solu Todd-Hewitt broth as stock solution. 50 mg of hydroxylapa tions are grown in Todd-Hewitt broth at 37°C. from overnight tite pearls (HA: Macro-Prep Ceramic Hydroxylapatite, 80 single colony cultures. micron, of BioRad) are washed once with 1 ml of sterile HO 0260 Bacteria stock solutions are sonicated for 15 sec at and three times with 1 ml of absorption buffer sterilised by 30 W, centrifuged for 5 min at 8000 rpm, the pellet then filtration (5 mM KC1, 1 mM CC1; 0.1 mM MgCl; 1 mM re-suspended in PBS, again centrifuged and re-suspended in KHPO, pH 7.2) (cf. Berry & Siragusa (1997); Appl. Envi a sterilized 1:1 mixture of culture medium and human saliva ron. Microbiol. 63, 4069-4074).2 ml of the bacterial solution or in PBS (phosphate buffered saline, pH 7.2-7.4) and media are centrifuged (10,000 rpm, 5 min) and washed twice with to yield a final concentration of 10-10/mlbacteria. A part is adsorption buffer and are then resuspended in 1 ml of adsorp plated for CFU (colony forming units) determination. tion buffer. This solution is combined with the hydroxylapa tite pearls suspended in 1 ml of adsorption buffer and incu a) Influence on Planctonic Cultures bated, with slight shaking, for 30 min at 37° C. After the HA 0261. Therest of this solution is either used alone or mixed pearls have settled, the Supernatant is removed. The HA with different amounts of Scleroglucan (SC) or Triclosan pearls are washed once with adsorption buffer and are then (TR) and mixtures thereof as indicated in Tables 9 or as a incubated, with slight shaking, for 30 min at 37°C. with 1 ml control with the appropriate volumes of PBS only. After 2 min of adsorption buffer containing 0.0001-1% of the Scleroglu at 37° C. bacteria are centrifuged (5 min at 8000 rpm), the can used in example 7 and 0.0001%-0.3% of Triclosan and as pellet washed by PBS, re-centrifuged and suspended in a controls Glucan or Triclosan alone and absorption buffer sterilized mixture of culture medium/human saliva 1:1 or alone (see table b below). with medium and PBS to yield the test (TST) solution or the 0257. After the HA pearls have settled, the supernatant is control solution (CTRL). Parts of TST and CTRL-solutions removed and replaced with 0.5 ml absorption buffer contain are plated and the rests are added to borosilicate glass plates ing 0.05% Tween-80. HA pearls are then incubated in the cold mounted in flow-chambers essentially as described by and under occasional Vortexing. After 15 min 4.5 ml absorp Deckeretal J. Period Res 40:373 (2005) and incubated for 60 tion buffer are added, HA-pearls are allowed to settle and the min at 37° C. Test plates are shortly washed in water and Supernatant is plated accordingly on BA plates for quantifi densities and cell vitality of adsorbed cells determined cation. The results are shown in the following table; compo accordingly (see Decker et al 2005). sitions of the invention are marked with an asterisk (*). b) Influence on Attached Cells TABLE b 0262 Plates incubated for 60 min with CTRL cultures as Desorption of microorganisms in presence of Scleroglucan (S) described above are removed, shortly washed in PBS and then and/or Tricosan (T). No. of colonies immersed for 2 minat37°C. into a mixture of PBS containing agent in liquid S. militans S. mitis S. anguinostis S. Sanguis SC, TR or mixtures of SC/TR as described in Tables 9. Then plates are shortly washed in water and processed for density Ole 0.0001% S, 0.0001% and vitality assessment as described above. T: O.OOO2% S c) Results O.OOO2% T 0.001% S, 0.0003% 0263. In the planctonic phase the combinations of SC/TR T: show the best antibacterial effect as measured by CFU reduc tion. US 2009/0156563 A1 Jun. 18, 2009

0264. Adhesion of vital cells to glass plates is lowest when pre-treating bacteria in the planctonic phase with combina TABLE 9.3 tions of SC/TR. Influence on cell desorption when treating bio-film of adsorbed 0265. After treatment of the biofilm the amount of vital bacteria with Scleroglucan (SC) and/or Triclosan (TR); % cell cells is lowest when using combinations of SC/TR. density and 90 cell viability of untreated control agent in S. S. TABLE 9.1 liquid S. militans S. mitis angutinosus sanguis S. Sobrinus

Ole Influence on planctonic phase Scleroglucan (S) andfor 0.0001% S, Triclosan (T); No. of colonies 0.00019. T: O.OOO2% S O.OOO2% T agent in S. S. 0.001% S, liquid S. militans, S. mitis, angutinosus, Sanguis S. Sobrinus 0.0003% T: O.OO13% S O.OO13%T Ole 0.01% S, 0.0001% S, 0.003% T: 0.00019. T: O.O13% S O.O13%. T O.OOO2% S 0.1% S, O.OOO2% T 0.03% T: 0.13% S 0.001% S, 0.13% T 0.0003% T: O.OO13% S O.OO13%T 0268. After treatment of the biofilm the relative amount of 0.01% S, vital cells is lowest when using combinations of SC/TR. O.OO39, T: 1. An antibacterial composition for contact with the O.O13% S mucosa or other tissues of the oral cavity, comprising O.O13%T a) a glucan, in an amount of 0.001 to 0.2%, relative to the 0.1% S, weight of the total composition, and 0.03% T: b) a bactericide selected from the group consisting of ben O.13% S Zoic acid, its salts and esters; propionic acid and its salts; O.13% T Salicylic acid and its salts; Sorbic acid and its salts; formaldehyde; paraformaldehyde; o-phenylphenol and its salts; inorganic Sulphites and hydrogen Sulphites: 0266. In the planctonic phase the combinations of SC/TR Sodium iodate; chlorobutanol, 4-hydroxybenzoic acid show the best antibacterial effect as measured by CFU reduc and its salts and esters; 3-acetyl-6-methylpyran-2.4 tion. (3H)-dione; formic acid; sodium formiate: dibromo hexamidine and its salts; undec-10-enoic acid and salts; TABLE 92 hexetidine; 5-bromo-5-nitro-1,3-dioxane: bronopol; 2,4-dichlorobenzyl alcohol; triclocarban; 2.4.4'- Influence on cell adsorbtion when treated in planctonic phase; trichloro-2'-hydroxy-diphenylether (Triclosan); Scleroglucan (SC) and/or Triclosan (TR); % cell density and % 4-chloro-3,5-xylenol; imidazolidinyl urea; poly(1-hex cell viability of untreated control amethylenebiguanide hydrochloride); 2-phenoxyetha agent in S. S. nol; hexamethylenetetramine; methenamine 3-chloroal liquid S. militans, S. mitis, angutinosus, Sanguis S. Sobrinus lylochloride: 1-(4-chlorophenoxy)-1-(imidazol-1-yl)-3, 3-dimethylbutan-2-one; 1,3-bis(hydroxymethyl)-5,5- Ole 0.0001% S, dimethylimidazolidine-2,4-dione; benzyl alcohol; 0.00019. T: 1-hydroxy-4-methyl-6(2,4,4-trimethylpentyl)-2-pyri O.OOO2% S don or its monoethanolamine salt; methyldibromoglu O.OOO2% T 0.001% S, taronitrile; bromochlorophen; 4-isopropyl-m-cresol; 0.0003% T: mixture of 5-Chloro-2-methyl-isothiazol-3(2H)-one O.OO13% S and 2-methylisothiazol-3(2H)-one with magnesium O.OO13%T chloride and magnesium nitrate; clorophene: 2-chloro 0.01% S, O.OO39, T: acetamide; chlorhexidine and its digluconate, diacetate O.O13% S and/or dihydrochloride: 1-phenoxypropan-2-ol; alkyl O.O13%T (C-C) trimethyl ammonium bromide and/or chlo 0.1% S, ride; 4,4-dimethyl-1,3-oxizalidine; N-(hydroxym 0.03% T: O.13% S ethyl)-N-(dihydroxymethyl-1,3-dioxo-2,5-imidazolidi O.13% T nyl-4)-N'-(hydroxymethyl)urea; hexamidine and its salts; glutaraldehyde; chlorphenesin; sodium hydroxymethylglycinate; benzethonium chloride; ben 0267. The relative amount of vital cells adsorbing to glass Zalkonium chloride, bromide and/or saccharinate; ben is lowest when using combinations of SC/TR. Zylhemiformal, listerine, alexidine, and essential oils US 2009/0156563 A1 Jun. 18, 2009 19

including thymol, geraniol, carvacrol, citral, hinokitiol, wherein n is a number which provides the Scleroglucan com eucalyptol, eugenol, menthol, or catechol. ponent with a mean molecular weight of one million to twelve 2. A composition comprising million. a) 0.001 to 0.2% by weight, relative to the weight of the 11. A composition according to claim 2, wherein compo total composition, of a Scleroglucan of mean molecular nent (a) is a Scleroglucan which is obtained by cultivation of weight one million to twelve million; microorganisms, in the form of the plant-pathogenic fungi b) a cosmetically or pharmaceutically acceptable carrier, imperfecti Sclerotium rolfsii. and 12. A composition according to claim 5 wherein said com c) a further component selected from the group consisting position is a skin care composition, shampoo and/or hair of lactic acid, lactate and 1.2-pentanediol conditioner composition in the form of a gel or viscous liquid. in an amount of 0.005 to 3% by weight, relative to the 13. A composition according to claim 2 wherein said com weight of the total composition. s position is in the from of an aqueous lotion, a water-in-oil or an oil-in-water emulsion, an oil or oil-alcohol lotion, a vesicu 3. A composition according to claim 2 comprising lar dispersion of an anionic or nonionic amphiphilic lipid, an a) 0.005 to less than 0.05% by weight, relative to the weight aqueous, aqueous-alcohol, alcohol or oil-alcohol gel, a solid of the total composition, of a Scleroglucan of mean Stick or an aerosol. molecular weight one million to twelve million; and b icall h icall b1 14. A composition according to claim 13 wherein said ) a cosmetically or pharmaceutically acceptable carrier. composition is a water-in-oil emulsion or said oil-in-water 4. A composition according to claim 1 comprising a bac- emulsion, the cosmetically acceptable carrier of component tericide as defined as component (b) of claim 1, and wherein b) comprises 5 to 50% of an oil phase and 47 to 94.95% of the Weight ratiobactericide:glucan component (a) is from the water, each based on the total weight of the composition, and range 1:10-10:1. optionally a further component acting as an emulsifier and/or 5. A composition according to claim 2 wherein said com- Surfactant. position is in the form of a cosmetical or dermatological skin 15. A composition according to claim 1 wherein said com composition, containing as component d) a cosmetically or position additionally comprises at least one Substance dermatologically acceptable carrier. selected from the group consisting of antiphlogistic agents, 6. A composition according to claim 1 wherein said com- antiinflammatory agents, vitamins, antioxidants, antipsori position is an oral care composition, a feminine hygiene atic agents, further skin actives, cell proliferation regulators, composition, a composition for the treatment of a medical antiallergic, UV protecting, moisturizing, antiaging agents, implant a composition for the treatment of an oral implant, an DNA-protectants, emollients, additional thickening agents, eye drop formulation, an eye make-up composition or an eye moisture-retention agents, film formers, preservatives, per make-up remover composition. fumes and colourants. 7. An oral care composition according to claim 6, wherein 16. A composition according to claim 12, wherein said said composition is a tooth paste or gel, a mouth wash, a composition is an anti-inflammatory skin care preparation, a gargle, an inhalant, a denture or implant or brace or a cleaner Sunscreen lotion, an after-Sun skin care preparation, a revital thereof, or an adhesive paste. izing skin care preparation, or an anti-aging skin care prepa 8. An oral care composition according to claim 7, addition- ration. ally containing a further agent Suitable to inhibit alkaline 17. A composition according to claim 1 containing the phosphatase, wherein said agent is selected from the group scleroglucan in an amount between 0.05 and 0.1% by weight consisting of polyanionic polysaccharides, polyanionically- of the total composition. derivatised polysaccharides, phosphochitosanes and phos 18. A composition according to claim 8 formulated as a phochitosanes. microemulsion or dispersion of nano-scaled particles. 9. A composition according to claim 1, wherein the bacte- 19. (canceled) ricide of component b) is selected from the group consisting 20. A process for the preparation of a cosmetical or derma of Triclosan, chlorohexidin, hexetidine, and listerine. tological formulation for the treatment or prevention of 10. A composition according to claim 2, characterized in inflammatory or allergic conditions, skin-aging, skin irrita that component (a) is a Scleroglucan having a three-dimen tion or inflammation by Sun exposure, wrinkles, or for wound sional crosslinked triple helix structure, having the structural healing, wherein said process comprises formula adding 0.005 to less than 0.05% by weight, relative to the weight of the total formulation, of a Scleroglucan of mean molecular weight one million to twelve million together with lactic acid, a lactate and/or 1.2-pen tanediol, to a cosmetically or dermatologically accept O able carrier and mixing thoroughly. 21. A concentrate for the preparation of a cosmetic or OH pharmaceutical formulation, wherein said concentrate com HO prises lo R -o a) 0.3 to 3.0% by weight, relative to the total weight of the concentrate, of a Scleroglucan of mean molecular weight OH OH one million to twelve million; b) a cosmetically or pharmaceutically acceptable aqueous carrier, and US 2009/0156563 A1 Jun. 18, 2009 20

c) lactic acid or a lactate and/or 1.2-pentanediol in a weight b) a cosmetically or pharmaceutically acceptable carrier; ratio relative to component (a) from the range 2:1 to and 20:1. c) a further component selected from the group consisting 22. A method for reducing the number of bacteria and/or of lactic acid, lactate and 1.2-pentanediol, in an amount minimise adhesion of bacteria in mucosal or oral environ of 0.02 to 1.0% by weight, relative to the weight of the ments which method comprises contacting a composition total composition. 25. A composition according to claim 6 wherein said com according to claim 1 with the mucosa or oral tissue. position is in the form of an aqueous paste or gel oranaqueous 23. A composition according to claim 2 comprising liquid. a) 0.001 to 0.1% by weight, relative to the weight of the 26. A process according to claim 20 for the preparation of total composition, of a Scleroglucan of mean molecular a cosmetic ordermatological formulation for the treatment or weight one million to twelve million; prevention of inflammatory or allergic conditions, skin-ag b) a cosmetically or pharmaceutically acceptable carrier, ing, skin irritation or inflammation by Sun exposure, wrinkles, and or for wound healing, wherein said process comprises c) a further component selected from the group consisting adding 0.001 to 0.2% by weight, relative to the weight of of lactic acid, lactate and 1.2-pentanediol, in an amount the total formulation, of a beta-1,3-scleroglucan of mean of 0.02 to 1.0% by weight, relative to the weight of the molecular weight one million to twelve million, together total composition. with lactic acid, a lactate and/or 1.2-pentanediol, to a 24. A composition according to claim 23 comprising cosmetically or dermatologically acceptable carrier and a) 0.005 to less than 0.05% by weight, relative to the weight mixing thoroughly. of the total composition, of a Scleroglucan of mean molecular weight one million to twelve million;